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Ceramide-1-phosphate (C1P) is a bioactive lipid that has been implicated in many 
biological processes. Our laboratory has conclusively demonstrated its role in 
inflammation via activation of cPLA2α. The only known enzyme to date responsible for 
direct synthesis of C1P is ceramide kinase. Very little was known about this enzyme in 
terms of its enzyme kinetics substrate specificity.  As CERK is an enzyme that acts on 
membrane lipids, its kinetics cannot be studied using standard bulk dilutions methods. 
Thus we developed a surface dilution approach using Triton X 100 mixed micelles for 
studying the kinetics of CERK.  We discovered that ceramide kinase has an affinity for 
naturally occurring long chain ceramides while ceramides containing shorter than 8 
carbons are very poor substrates for the enzyme. Also of note is the discovery that there is 
xv 
now discrimination between the naturally occurring long chain ceramides leading to the 
conclusion that the preponderance of D-e-C16 C1P in cells are due to an availability effect. 
We also investigated the chain length specificity of interaction between C1P and cPLA2α. 
Our data indicate that cPLA2α is activated by C1P’s containing acyl chains longer than two 
carbons. The study showed C2 C1P as being unable to activate cPLA2α thus establishing a 
tool for the investigation of cPLA2α dependent and independent effects of C1P. In the 
course of the study we investigated the ethanol/dodecane delivery system as a means of 
safely delivering lipids to cells. Our data conclusively demonstrate that this delivery 
system successfully delivers lipids to the internal membranes where their biological action 
takes place and that at low lipid concentration (<1µM), is non toxic to cells. A significant 
technical hurdle in the study of C1P was the lack of accurate and reproducible method of 
quantitatively and qualitatively analyzing the lipid. Using a mass spectrometric approach 
we developed an accurate technique that now allows us to quantify the lipids in cells. 
Using this and radiolabeling studies we discovered evidence for production of C1P from 
S1P via an acyl transferase pathway. Further studies are currently being carried out to 
identify the enzyme/s responsible for this pathway. 
   
 
 
1 
INTRODUCTION 
 
 
LIPIDS AND THEIR MANY FUNCTIONS 
 
 
Of the major classes of biomolecules that make up a cell (nucleic acids, proteins, lipids and 
carbohydrates), lipids until recently, were not given the consideration deserved. While 
nucleic acids and proteins are necessary for cell survival, it is the lipids that are responsible 
for a cells existence. These are the molecules that through their special properties of self 
aggregation, walled off sections of the primordial soup giving rise to separate 
microenvironments that eventually became life. Thus if it is not for the lipids, life as we 
know would not exist. 
 
Lipids are broadly defined in most textbooks as any lipophylic naturally occurring 
molecule. This broad category of compounds include fats, oils, waxes, cholesterols, sterols, 
fat soluble vitamins, mono and diglycerides etc. A much more refined definition of lipids 
would be that they are hydrophobic or amphiphilic small molecules that originate entirely 
or in part from either ketoacyl or isoprene groups. Using this definition, lipids can be 
categorized into eight different classes as fatty acyls, glycerolipids, glycerophospholipids, 
sphingolipids, saccharolipids, polyketides, sterol lipids and prenol lipids. 
Glycerophospholipids are the principal lipids found in membranes. Of the phospholipids, 
PE, PS and PI are found primarily in the inner leaflet of the membranes while PC is mainly 
found on the outer leaflet. While phospholipids do not flip between the membranes on their 
2 
own, the action of a group of enzymes called scramblases can catalyze this movement (1).  
In addition sphingomyelin, ceramides and sterols (mainly cholesterol) are also membrane 
constituents in animal cells. High caloric content of triglycerides have made them the ideal 
choice for energy storage by animals. In addition to these functions, certain lipids have 
other attributes specific to them. Vitamins A, D, K and E are essential isoprene based 
lipids and are stored in the liver and fatty tissues. Acyl carnitines are involved in the 
transport and metabolism of fatty acids in and out of mitochondria where they undergo 
beta oxidation. Polyprenols and their phosphorylated derivatives are important in 
transportation. Cardiolipins, a lipid that is found in the inner mitochondrial membranes are 
thought to be important in the activation of enzymes involved in oxidative 
phosphorylation. 
 
SPHINGOLIPIDS 
 
Sphingolipids are a major class of lipids that are conserved in all eukaryotic organisms. 
Sphingolipids are also found in some prokaryotic organisms, especially the genus 
Sphingobacterium (2). Loss of the ability to synthesize sphingolipids are lethal and has 
been shown to cause cell death in yeast (3) cell death in fly (4) and embryonic lethality in 
mouse (5).  
 
The main classes of sphingolipids are the long chain bases, long chain base 1 phosphates, 
ceramides and their phosphates, sphingomyelins and glucosyl and galactosyl ceramides. 
3 
All sphingolipids are characterized by the presence of a sphingoid backbone containing a 
primary hydroxyl group at C1, an amino group on C2 and a secondary hydroxyl group on 
C3. This constitutes a hydrophilic head group and a hydrophobic tail group. All ceramide 
species contain an acyl chain attached to the sphingoid backbone via an amide bond 
through the amino group. The high stability of the amide bond renders ceramide species 
resistant to alkaline hydrolysis allowing for selective purification of sphingolipid species 
from glycerolipids in biological samples. The primary hydroxyl group allows for the 
attachment of various head groups via an ester or ether linkage. Specific examples include 
attachment of phosphocholine head group via a phosphodiester linkage giving rise to 
sphingomyelin, attachment of one or more glucose or galactose groups via an ether 
linkage, giving rise to multiple glucosyl or galactosyl ceramides. 
 
A simple abbreviated nomenclature for sphingolipids is defined by the lipidmaps 
consortium (6). Accordingly the number of hydroxyl groups are defined by d (di), t (tri) 
followed by the number of carbons in the sphingoid backbone and then the number and 
position of the double bonds. For example, d18:0 for sphinganine d18:1∆4 for sphingosine, 
d18:1∆4,8 for sphingadienine and t18:0 for 4D-hydroxysphinganine. Sphingoid base 1-
phosphates are denoted as d18:1-P. When denoting sphingosine or any other species 
containing the sphingosine backbone, the position of the double bond is generally omitted. 
When denoting N-acylated sphingolipids, after the denotation for sphingoid backbone the 
number of carbons of the acyl chain is indicated followed by the number of double bonds 
4 
and their position. For example ceramide species with 18 carbon acyl chain with one 
double bond is denoted as d18:1/18:1 
 
Table 1: General structure of sphingolipids. 
R1 R2 R3 
=OH 
Ceramide 
= Glucose 
Glucosyl ceramide 
= Galactose 
Galactosyl ceramide 
 = phosohatidyl choline 
Sphingomyelin 
Alkyl chain 
Acyl chain 
length 
C2 to C26 
Saturated or 
unsaturated 
 
 
The major form of the sphingoid backbone contains a trans double bond at the 4,5 position.  
The desaturation of the 4,5 bond  occurs at a later stage of the denovo synthesis of 
sphingolipids. Thus significant quantities of 4,5 dihydro sphingosine  and diydro ceramide  
species are also found in all of the eukaryotic cells. The major sphingoid base found in 
mammals are d18:1∆4 while plant and fungi predominantly has phytosphingosine which 
carries an OH group at the C4 position (t18:0). Mammals do have phytosphingosine; 
however they are limited mainly to the skin small intestines and the kidney. In addition 
mammalian skin has an unusual sphingoid base that contains an OH group at the 6 position 
(6-hydroxy-4-sphinganine) denoted t18:1∆4 (7).  Sphingoid base chain length can also vary 
between species. Among mammals it is predominantly 18. However 16, 18 and 20 carbons 
are found in yeast (8). 
5 
SYNTHESIS AND METABOLISM OF SPHINGOLIPIDS. 
 
De novo synthesis of sphingolipids occur in the ER and start with the condensation of 
serine and palmitoyl Co-A by the action of serine palmitoyltransferase to produce 3-
ketosphinganine. This is the rate limiting step in the synthesis of sphingolipids. 3-
ketosphingainine is then reduced, N-acylated and desaturated to add a 4,5 double bond in a 
series of enzymaticaly catalyzed steps that include ceramide synthase (CerS) to give 
ceramide in the cytosolic leaflet of the ER (9). Ceramide thus synthesized is transported to 
the golgi where further modification produce complex sphingolipids like 
glucosylceramides and sphingomyelins. This transport of ceramide to the golgi is carried 
out either via a vesicular transport system involving COPII coated vesicles (10) or by non 
vesicular means via the ceramide transport protein (CERT) (9). 
 
Mammals have six ceramide synthases currently identified with variable specificity for 
different acyl CoA groups. CerS1 for C18, CerS5 and 6 for C16, and CerS 2 and 4 for C22 
and C24 (11-13). The attachment of the phosphocholine group to produce sphingomyelin is 
carried by sphingomyelin synthases of which two are present in mammalian cells SMS1 
and SMS2 (14, 15). Glucosylation is carried out by the ceramide glucosyltransferase (16) 
and galactosylation is carried out by ceramide galactosyltransferase (17). Further 
glucosylation and galactosylation of glucosyl and galactosyl ceramide leads to hundreds of 
glycosphingolipids. Ceramide is phosphorylated in mammalian cells to produce ceramide-
6 
1-phosphate via a kinase and a non kinase pathway (18). Ceramide kinase is the only 
known mammalian enzyme to date to produce ceramide 1 phosphate(19). 
 
 
 
Figure 1. The synthesis and metabolism of sphingolipids. Ceramide is the central 
molecule in sphingolipid metabolism giving rise to all the major forms of sphingolipids in 
the cell.  
Modified from: Pettus, et al. Biochim, Biophys Acta 2002, 1585: 114-25. 
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LIPIDS AND CELL SIGNALLING 
 
The ability of lipids to act as signaling molecules has been known for a long time. As early 
as 1930 cysteinyl leukotrienes have been known as slow reacting substances of 
anaphylaxis. Around the same time prostaglandins were found to cause vasodilation. It is 
now known that all these are metabolites of arachidonic acid. Thus a single lipid can have 
diverse downstream effects based on final products of its further metabolism. 
 
Phosphatidylinositols are another well known group of lipid second messengers. Around 
1980 it was discovered that phosphatidylinositol 4,5 bis phosphate could be hydrolyzed by 
phospholipase C (PLC) producing diaclyglycerol and inositol-1,4,5-tris phosphate. Both of 
these products are second messengers. DAG activates protein kinase C (PKC) while l 
Ins(1,4,5)P3 causes Ca+2 release from internal stores. Other inositol polyphosphates are 
involved in different signaling events. For example PtdIns(3,4,5)P3 is a signaling molecule 
that modulates cell growth, proliferation and motility. In addition to acting as direct 
signaling molecules, phosphoinositides act as localization agents for membrane signaling 
complexes. Another very potent signaling lipid is lysophosphatidic acid (LPA). These can 
act in an autocrine and paracrine manner through GPCR (20, 21). 
 
8 
The sphingolipids ceramides and sphingosines are lipids that have proapoptotic and 
antiproliferative actions. Their phosphorylated compounds ceramide 1 phosphates (C1P) 
and sphingosine 1 phosphate (S1P) are also potent signaling molecules. S1P is a well 
known potent cell proliferative agent while C1P among other things is a potent inducer of 
inflammation. 
 
Disruptions and unusual changes in signaling lipids contribute to progression of diseases 
like chronic inflammation, autoimmunity, allergy, cancer atherosclerosis, hypertension, 
heart hypertrophy and metabolic and degenerative diseases etc. 
 
LIPID SIGNALING AND INFLAMMATION. 
 
Affecting lipid metabolisms to treat inflammation is not new to western medicine. Records 
as long ago as 400 BC from the Father of modern medicine, Hippocrates show the use of a 
brew from willow tree (Salix alba) to relieve fever and pain. Many centuries later the 
active ingredient was found to be salicilin, which in the body gets converted to salicylic 
acid that binds a pocket in cyclooxygenase leading to its irreversible inhibition and thereby 
shutting down prostaglandin synthesis. The identification of the binding site also led to the 
discovery of the highly effective COX-2 inhibitors. 
 
Some of the major lipids involved in the inflammatory response are prostaglandins, 
leukotrienes and thromboxanes all of which are metabolites of arachidonic acid. 
9 
Arachidonic acid is produced by the hydrolysis of phosphatidylcholine containing 
arachidonic acid at the Sn2 position by the action of cPLA2. Upon receipt of an 
inflammatory stimulus a whole cascade of signaling events ultimately lead to the increase 
in intracellular Ca+2 through the opening of store operated calcium channels. This leads to 
the activation of a whole host of lipid enzymes which include PKC, CERK, 5-lipoxygenase 
and prostaglandin H2 synthase (PGH2) thus priming the cell for the inflammatory cascade. 
cPLA2 is activated by Ca+2 which neutralizes charges on the enzyme allowing it to bind PC 
rich membranes. This association is further enhanced by the action of ceramide kinase 
which produces C1P that increases the residence time of cPLA2 once it binds membranes. 
In addition multiple protein kinases phosphorylates cPLA2(22) which further supports its 
movement to the golgi peri nuclear region. Upon binding membranes, the activated cPLA2 
hydrolyses PC containing AA at the Sn2 position thus liberating AA. AA takes part in 
further metabolism to produce prostaglandins, thromboxanes and leukotrienes. These 
eicosanoids give rise to the classical features of inflammation and promote a wide range of 
disease states including chronic inflammation, allergy, cardiovascular diseases and 
cancer(23). Eicosanoids act extracellularly through GPCR. These inflammatory mediators 
promote bronchial constrictions, increased vascular permeability and diameter and the 
invasion of leukocytes which when in excess cause tissue destruction in late allergy and 
inflammation(24) 
10 
 
Figure 2.  Biosynthesis and Biological effects of the various prostaglandins. Upon the 
receipt of a stimulus cPLA2α is translocated from the cytoplasm to the golgi membrane 
where it liberates arachidonic acid from PC. This AA is then acted upon by the various 
prostaglandin and thromboxane synthases to produce the various prostaglandins and 
thromboxanes that in turn give rise to a multitude of biological responses. 
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CHAPTER 1:  Ceramide Kinase and Ceramide-1-Phosphate 
 
 
INTRODUCTION 
 
The sphingolipid, C1P, is a direct metabolite of ceramide produced in the mammalian 
cells. The only known pathway for it’s synthesis at present is via the phosphorylation of 
ceramide by ceramide kinase (CERK) (Figure 1). CERK was first described as a lipid 
kinase found in brain synaptic vesicles in 1989 by Bajjalieh and coworkers (25). This 
research group demonstrated that this activity was specific for the conversion of ceramide 
to C1P without effects on the closely related glycerol lipid, diacylglycerol (25). Just 
months after this initial finding, Kolesnick and coworkers reported the existence of C1P in 
human leukemia (HL-60) cells (26). They demonstrated that during stimulation, C1P was 
produced from ceramide derived from sphingomyelin, but not from glycosphingolipids. 
Later the same year, Kolesnick and coworkers also reported a CERK activity 
distinguishable from diacylglycerol kinase (DGK) activity in HL-60 cells verifying the 
findings of Bajjalieh and coworkers (27). To date, in mammalian cells, C1P has only been 
shown to be derived from the phosphorylation of ceramide by a specific CERK activity.    
  
In 2002, the cDNA sequence for CERK was cloned by Sugiura and coworkers from Jurkat 
acute T-cell leukemic cells (19). The enzyme was found to be mainly expressed in heart, 
kidney, brain, and hematopoietic cells (19). Human CERK was also found to be a 537 
12 
amino acid protein closely related in structure and amino acid homology to sphingosine 
kinase 1 (SphK1) and 2 (SphK2). CERK was found to contain the five conserved domains 
(C1-C5) previously identified for SphK1 and 2. The first three of these domains, C1-C3, 
are found within a putative diacylglycerol kinase domain (DGK domain) (amino acids 
126-342). The C4 region consists of a short 28 amino acid stretch designated the central 
homology region located just after the DGK catalytic domain, and the C5 region (amino 
acids 385-537) is located in the C-terminus of the enzyme (19) (Figure 1.1).  
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Figure 1.1: Important structural features of CERK: Schematic representation of the 
domain structure and conserved sequences of CERK with the corresponding primary 
structure. PH-Domain; Pleckstrin Homology domain (yellow), DAGK catalytic domain; 
diaclyglycerol kinase catalytic domain (purple), SphK C1 to C5 conserved regions within 
CERK (grey), calmodulin binding region (maroon).  
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REGULATION OF THE ACTIVITY OF CERAMIDE KINASE 
 
CERK also contains additional conserved regions across several species (M. musculus, D. 
melanogaster, C. elegans, and O. sativa). These include a PH-domain in its N-terminus 
known to bind the β/γ subunit of heterotrimeric G-proteins, phosphoinositol-4,5-
bisphosphate, and phosphorylated tyrosine residues (19). CERK is a calcium stimulated 
enzyme. However there are no binding sites for Ca+2 on CERK but contains a 
calcium/calmodulin binding motif of the 1-8-14 type B spanning residues 422-435 
((F/I/L/V/W) XXXXXX (F/A/I/L/V/W) XXXXX (F/I/L/V/W) with a net charge of 2+ to 4+) 
(19). These conserved domains have been shown to play a regulatory function for the 
enzyme. For example, Igarashi and coworkers and Bornancin and coworkers have both 
demonstrated that the PH-domain is required for the activity of CERK in vitro as well as 
proper localization of the enzyme in cells (28, 29). In regards to the calmodulin binding 
motif, Igarashi and coworkers recently demonstrated that calmodulin interacts with CERK 
and acts as a calcium “sensor” for the enzyme (30). Thus, these conserved domains play 
distinct roles in regulating CERK activity in vitro and in cells.  
 
CERK has several putative phosphorylation sites of which some are highly conserved 
(Table 1).  Treatment of A549 cells transfected with recombinant CERK has shown CERK 
to be phosphorylated in response to PKC and PKA agonists (Figure 1.1) 
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Table 1.1: Putative phosphorylation sites on CERK 
 
Protein Kinase Putative phosphorylation site 
PKC S72*, T118*, T127*, S230*, S300***, S340* 
PKA S424** 
 
* Conserved in mouse CERK 
**Conserved in both mouse and drosophila CERK. 
***Conserved in SPHK of all multicellular organisms 
 
 
Another less understood mechanism of regulation of CERK is via lipid co-factors a. It has 
been known for quite some time that cardiolipin was able to activate CERK and in fact in 
its absence the in vitro activity of the enzyme is absent. A literature survey revealed that 
the motif KNKEKK is capable of binding cardiolipin (31). A similar motif (KDSEKK-
Figure 1.1)  is present on CERK that may have a role in binding to cardiolipin. The serine 
found on this (S300) sequence is highly conserved in all eukaryotes and is a putative PKC 
phosphorylation site.  CERK has been shown to be phosphorylated in response to the PKC 
agonist PMA and also in response to forskolin (Figure 1.2). Site directed mutagenesis of 
the S300 to E resulted in a complete loss of enzyme activity where as it’s mutagenesis to A 
did not affect the enzyme activity by much (Figure 1.3).  
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Figure 1.2: CERK is phosphorylated in response to PKA agonist forskolin and PKC 
agonist phorbol myristoyl acetate. A549 cells transfected with 6X His and V5 tagged 
CERK were treated with either the pan PKC agonist PMA or the PKA agonist forskolin. 
The cells were lysed and ceramide kinase was subjected Ni-NTA purification. The proteins 
were separated by SDS PAGE and subjected to autoradiography.  In a parallel gel was 
subjected to western blotting to confirm the presence of CERK. Following 
autoradiography the P32 labeled CERK bands were excised and counted by scintillation. 
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Figure 1.3: Serine 300 is a possible regulator of activity of CERK.  A549  cell lysates 
were tested for ceramide kinase activity  following transfection with wild type, S300A or 
S300E mutants of CERK. Western analysis revealed similar levels of recombinant CERK 
present in the lysates. 
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BIOLOGICAL ACTIVITIES ATTRIBUTED TO C1P 
 
In the last few years, a large number of reports have demonstrated distinct biological 
mechanisms regulated by C1P. For example published findings from our laboratory 
demonstrated that C1P is a direct activator of cPLA2α through interaction with the 
C2/CaLB domain (32). These results coupled with the previous findings that CERK/C1P 
pathway is required for PLA2 activation in response to calcium ionophore and cytokines 
(33) demonstrated that C1P is a “missing link” in the eicosanoid synthetic pathway. 
Mechanistic studies demonstrated that the interaction of C1P and cPLA2α was very 
specific as closely-related lipids and metabolites were unable to activate cPLA2α in vitro 
and in cells (32, 34). Furthermore, these studies demonstrated that C1P interacted with 
cPLA2α in the C2 domain via a novel and previously undescribed interaction site. Lastly, 
the studies also defined the mechanism of cPLA2α activation: 1) decreasing the 
dissociation constant of cPLA2α with membranes, and 2) acting in a manner similar to a 
positive allosteric activator (34). A role for CERK and its product, C1P, in a separate 
pathway of allergic/inflammatory signaling has also been recently reported in mast cells. 
Igarashi and coworkers demonstrated that treatment of RBL-2H3 cells or overexpression 
of CERK in these cells enhanced the degranulation induced by A23187 (35). 
  
Another biological mechanism regulated by CERK and C1P was demonstrated by 
Shayman and coworkers. Specifically, they demonstrated that CERK was activated in the 
context of phagocytosis in neutrophils after challenging the cells with formyl peptide and 
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antibody-coated erythrocytes (FMLP/EIgG) (36). Thus, these data demonstrated that C1P 
may play a distinct role in membrane fusion possibly explaining the early finding that high 
levels of C1P are found in synaptic vesicles (25).  
 
The first report of a biological effect for C1P was by Brindley, Gomez-Munoz, and 
coworkers. They demonstrated that short chain (not naturally found in cells) C1P induced 
DNA synthesis in Rat-1 fibroblasts (37). Later, Gomez-Munoz and coworkers also 
demonstrated that treatment of T17 fibroblasts with natural ceramide-1-phosphate induced 
a potent increase in DNA synthesis and the levels of proliferating nuclear antigen (38). 
The most recent report was from the Gomez-Munoz laboratory demonstrating that C1P 
prevented cell death in bone marrow-derived macrophages (BMDMs) after withdrawal of 
macrophage colony-stimulating factor (M-CSF)(39). Treatment of these cells with C1P 
effectively blocked the activation of caspases and prevented DNA fragmentation upon 
serum removal. In the same study, they also demonstrated that C1P treatment inhibited 
ceramide generation from acid sphingomyelinase (A-SMase). Lastly, A-SMase was shown 
to be a direct target of C1P inducing inhibition of this enzyme(39).  
 
In conclusion, C1P and ceramide kinase have recently been shown to play significant 
biological roles in a variety of cell signaling cascades. In this chapter, we describe the 
methodologies for examining CERK function and C1P-specific effects in vitro and tissue 
culture systems. 
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RECOMBINANT EXPRESSION OF CERK  
 
Principle 
 
Production of CERK of sufficient quantity and purity is essential for producing consistent 
and reproducible results for in vitro kinetic analysis. Currently, there are several ways to 
purify endogenous CERK. The first method was described by Bajjalieh and coworkers 
using membrane synaptic vesicles from rat brains(25). A second method involves 
extracting the membrane fractions that are generally high in CERK activity. Neither 
method produces CERK of sufficient purity or quantity for detailed kinetic analysis. In 
addition, there is currently an absence of an antibody for efficient immunoprecipitation of 
the enzyme. Recently, our laboratory has demonstrated that the use of recombinant 
technology is an option available to obtain CERK of sufficient quantity and purity for in 
vitro kinase assays.  
 
For large scale production of recombinant CERK, baculoviral-mediated expression in 
insect cells is recommended for several reasons. First, the post-translational modifications 
of insect cells are comparable to that of mammalian cells (Kost et al., 2005; Possee, 1997). 
This allows for CERK to be obtained in a form that resembles mammalian CERK. Second, 
insect cells can be cultured in large quantities allowing for large scale purification of 
CERK. Third, bacterially-expressed CERK may be contaminated by non-specific lipid 
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kinases due to aggregation unlike the use of baculovirus. Adenoviral-mediated expression 
of CERK is also the method of choice for the expression of CERK in human cell lines. 
However, adenoviral-mediated gene expression allows only for the transient expression of 
CERK as the adenoviral genome does not get incorporated into the genome. Furthermore, 
large quantities of recombinant CERK from human cells is costly in comparison to insect 
cells.  
 
Reagents 
 
Sf-9 cells and SF-900 media were obtained from Invitrogen Corporation. Sf-9 cells are 
stored in liquid nitrogen and the media is stored at 4°C until use. pBlueBac4.5/V5-His-
TOPO® vector, the pBlueBac4.5/V5-His-TOPO® TA kit, pcDNA™ 3.1D/V5-His-TOPO, 
pcDNA™3.1 Directional TOPO® Expression Kit and Back-n-BlueTM DNA were obtained 
from Invitrogen Corporation and are stored at -20°C. Cellfectin® was also obtained from 
Invitrogen Corporation and is stored at 4°C.  The pTRE Shuttle vector and BD Adeno-XTM 
Tet-Off Expression system 1, were purchased from Clontech and is stored at -20°C until 
use. MOPS, KCl, glycerol, Triton X-100, Imidazole, and PMSF are obtained from Sigma-
Aldrich and is stored at room temperature. Aprotinin, Leupeptin, and Pepstatin were also 
obtained from Sigma-Aldrich. These are stored at -80°C.   DTT was also obtained from 
Sigma-Aldrich and upon receipt a 500 mM solution is made, aliquoted and stored at -80°C. 
Ni-NTA resin was obtained from Qiagen Corporation. XK columns are purchased from 
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Amersham Biosciences. Anti-6XHis and Anti-V5 antibodies were obtained from Santa 
Cruz Biotechnology and are stored at 4°C. 
 
Buffers 
 
Cell Lysis buffer:  
10 mM MOPS, pH 7.2, 150 mM KCl, 10% Glycerol, 0.5% Triton X-100, 
0.001 mg/ml Leupeptin, 0.01 mg/ml Aprotinin, 0.005 mg/ml Pepstatin, 1 
mM PMSF 
 
Buffer A for Ni-NTA His purification (Ni-NTA wash buffer):  
10 mM MOPS pH 7.2, 150 mM KCl, 10% Glycerol 
 
Buffer B for Ni-NTA His purification:  
10 mM MOPS pH 7.2, 150 mM KCl, 10% Glycerol, 250 mM Imidazole 
 
Dialysis buffer: 
 10 mM MOPS pH 7.2, 150 mM NaCl, 2 mM EGTA, 50% glycerol, 1 mM 
DTT 
 
 
 RECOMBINANT EXPRESSION OF CERK IN INSECT CELLS. 
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Ceramide kinase was PCR amplified (high fidelity) from an A549 cDNA library and 
then cloned into pBlueBac4.5/V5-His-TOPO® vector using the pBlueBac4.5/V5-His-
TOPO® TA expression kit. The cDNA was verified by sequence analysis. To produce 
CERK baculovirus, this CERK plasmid is transfected into sf9 insect cells simultaneously 
with Back-n-BlueTM DNA using Cellfectin® transfection reagent in serum free medium 
following the manufacturers recommended protocol. Recombinant viral genome is 
produced through homologus recombination leading to the production of infective 
baculoviral particles. The recombinant virus is identified by the presence of blue plaques in 
the presence of X-gal. The viral particles from the individual blue plaques are used to 
infect new sf9 cells growing in separate wells of 12 well plates. DNA is extracted from a 
portion of the resultant P0 viral stock and PCR amplified  for 15 cycles (94°C, 30s; 58°C, 
30 s; 72°C, 1 min) using the primer pair 5’-TCGTCTGTGTCGGCGGAGAT-3’ and 5’- 
CTTTGCCACCAACCCAGAACG -3’ to verify the presence of the sequence of interest. 
The primers cross one exon/intron boundary eliminating the possibility of amplifying 
contaminating genomic DNA from Sf-9 cells. Presence of a 355 bp band upon gel 
electrophoresis of the PCR product verifies the presence of CERK in the viral genome. The 
remaining P0 viral stock from PCR verified viral particles are then amplified twice to 
produce 1 L of P2 viral stock. This viral stock is titered by endpoint dilution and is used to 
infect sf9 cells at a density of 1.2-1.5x106 cells/ml in a 50 ml culture. Optimal 
transfection/expression is determined at 1 MOI of baculovirus for 72 hours post infection.  
The cells are harvested by centrifugation at 400xg. 
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 RECOMBINANT EXPRESSION OF CERK ADENOVIRUS IN MAMMALIAN 
CELLS. 
 
Ceramide kinase cDNA library was obtained from an A549 cDNA library using high 
fidelity PCR and cloned into pcDNA™3.1D/V5-His-TOPO® vector using the pcDNA™3.1 
Directional TOPO® expression kit. CERK expression in the adenoviral genome was 
carried out using BD Adeno-XTM Tet-Off Expression system. CERK with V5 and 6XHis 
tags (on C-terminus) was excised from the pcDNA vector using BamHI and PmeI and 
inserted into the pTRE Shuttle vector. Recombinant CERK containing the adenoviral 
expression cassette was excised from pTRE shuttle and ligated to Adeno-XTM viral DNA 
according to manufacturer’s protocol and amplified in E. coli. After amplification in E. 
coli, the recombinant CERK adenovirus is obtained by transfection of the linearized 
adenoviral genome containing the recombinant CERK expression cassette into HEK 293 
cells, and the recombinant adenoviral particles produced are harvested according to 
manufacturer’s protocol. Cotransfection of mammalian cells with these adenoviral particles 
along with the Adeno Tet-Off® regulatory virus allows for the transient overexpression of 
CERK in mammalian cells. Optimal transfection/expression is determined at 150 MOI 
each of Adeno-CERK and Adeno Tet-Off® virus infecting 2 x 106 A549 cells growing in 
15 cm plastic culture dishes in normal A549 media (DMEM/RPMI containing 10% serum  
and 2% Penicillin/Streptomysin). The cells are exposed to the virus for 48 hrs and then 
harvested for CERK purification. 
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 PURIFICATION OF RECOMBINANT CERK. 
 
Recombinant CERK expressed in either of above methods can be purified using Ni-NTA 
affinity column chromatography. Large scale purification of baculoviral-mediated CERK 
expression in Sf-9 cells is recommended. The following protocol was used for large scale 
purification of CERK from infected Sf-9 cells. The cell paste is suspended in ten volumes 
of lysis buffer, and cells lysed by douncing 10 times per sample using a dounce 
homogenizer with a type B pestle. 100 ml sample is used at a time and kept chilled on ice. 
The lysates are then centrifuged at 16,000xg for 45 minutes at 4 °C. Simultaneously, 100 
ml of Ni-NTA superflow resin is equilibrated in 5 column volumes of Ni-NTA wash 
buffer. The supernatant is then batch bound with the equilibrated Ni-NTA for 1.5 hours at 
4 °C with nutation. The resin is then transferred to a 5 cm XK column, and the column is 
washed until baseline absorbance at 280 nm with Ni-NTA wash buffer at 4 ml/min flow 
rate using fast protein liquid chromatography (FPLC). Thereafter, the column is washed 
with a 19.5 mM imidazole wash buffer at 4 ml/min until baseline absorbance at 280 nm.  
CERK is eluted from the column using 250 mM imidazole in Ni-NTA wash buffer at 5 
ml/min flow rate collecting the elutions in fractions. The eluted fractions are analyzed by 
SDS PAGE to assess the purification and by western blotting to identify the presence of 
recombinant CERK using Anti-His and Anti-V5 antibodies. All fractions containing 
CERK are pooled, and DTT is added to a final concentration of 1 mM. The pooled samples 
are dialyzed against the dialysis buffer overnight at 4 °C with stirring using dialysis tubing 
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with a 12-14,000 molecular weight exclusion. The dialyzed sample is centrifuged at 
31,000xg to remove any precipitant, and the total protein is quantified by Bradford assay. 
The protocol yields recombinant CERK that is 60-70% (Figure 2) pure with a specific 
activity of approximately 0.19 (µmol C1P produced/min/mg protein) towards D-erythro-
C16:0 ceramide (Figure 3). Glycerol is added to the pooled samples to 50%. The samples 
are then aliquoted and stored at -80 °C. Under these conditions CERK is stable for 
approximately 1 year. Note: For mammalian cells the same protocol can be utilized, but a 
type A pestle or sonication is recommended for cell lysis. Furthermore, this is a one day 
procedure. The enzyme needs to be purified and stored at -80°C as soon as possible for 
stability purposes. 
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Figure 1.4: SDS PAGE analysis of Ni-NTA purified CERK from Sf-9 cells: Cell 
lysates were subjected to purification by 6XHis Ni-NTA purification. The pooled fractions 
with the highest levels of CERK were dialyzed overnight against the storage buffer. An 
aliquot of purified CERK was separated on a 10% SDS-PAGE gel followed by coomassie 
staining to visualize the purity of the protein. Lane 1: BenchMark Protein ladder, lane 2: 15 
µg protein, lane 3: 10 µg protein, lane 4: 5 µg protein, lane 5: 2.5 µg protein. 
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 IN VITRO KINETIC ANALYSIS OF CERK ACTIVITY USING MIXED 
MICELLAR ASSAYS 
 
Principle 
 
For the following assays D-erythro-C16:0 ceramide and adenosine triphosphate (ATP) 
are routinely utilized for kinetic analysis. However, in terms of solubility, D-erythro-C18:1 
ceramide is more soluble and better suited for measuring endogenous CERK activity in 
vitro. In the methods described here, the activity of CERK was assayed by measuring the 
levels of ceramide-1-phosphate formed using a detergent micelle system for substrate 
presentation. Since endogenous CERK acts on membrane lipids, the presentation of its 
substrate in this form compatible to a biological membrane is appropriate. When studying 
the activity of CERK, one has to take into account the enzymes diffusion in a 3D cellular 
matrix (locating the membranes) and the diffusion in 2D (locating and utilizing its 
substrate in the membrane) bound to the membrane. Thus, the true kinetic behavior of the 
enzyme is best studied using a model that takes into account both bulk and surface 
diffusion. Surface dilution kinetics, first introduced in 1973 by Dennis, is an excellent 
means of studying this type of enzyme behavior in vitro. This technique can be coupled to 
both detergent micelles and lipid vesicles, but the use of vesicles as a mean of delivering 
the substrate is not suitable for the study of kinetics of CERK for several reasons. First, the 
number of substrate molecules per vesicle is not constant. Second, substrate molecules in 
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the inner membrane are not accessible to the enzyme. Lastly, mixed vesicles lack 
uniformity in size. Mixed micellar assays are better suited for the study of kinetics in being 
uniform in size with the same number of substrate molecules being present in each micelle. 
Thus, mixed micellar assays are the method of choice for in vitro assays when studying the 
kinetics of CERK. 
 
β-octylglucoside and Triton X-100 are the two published methods for the presentation of 
substrate to CERK as mixed micelles (40, 41) β-octylglucoside based method is the 
traditional method used in the assay of CERK (40). This system would be ideal for 
investigating substrates of ceramide. However, molecular modeling studies have shown 
micelles of β-octylglucoside to have an irregular surface (42), thereby preventing equal 
presentation of all substrate molecules to the enzyme. This tends to be a drawback when 
studying the kinetics of a lipid kinase. Also compared to Triton X-100, β-octylglucoside 
has a very high CMC, thus the amount of detergent required to achieve CMC is about 100 
times greater.  
 
Compared to β-octylglucoside method, Triton X-100 micelles provide several advantages. 
First, they provide an inert surface for CERK. Second, the size of the micelles is relatively 
independent of ionic strength and temperature within the physiological range (43-45). 
Third, mixed micelles up to 20 mol% phospholipids are similar in structure to pure Triton 
X-100 micelles, but proportionally larger (43-45). Lastly, pure Triton X-100 micelles do 
not coexist with mixed micelles.  Thus, Triton X-100 is an excellent method of choice in 
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the assaying of CERK activity. Both the β-octylglucoside and Triton X-100 assays are 
detailed below. 
 
Reagents 
 
CERK was prepared as mentioned above using baculoviral-mediated expression 
followed by Ni-NTA 6XHis purication. Triton X-100 was obtained from Pierce 
Biotechnology as a 10% solution (~155 mM). D-erythro-C16:0 ceramide was from Avanti 
Polar Lipids. Upon receipt a 0.82mM solution is prepared by dissolving in CHCl3 and is 
stored at -20 °C until use. Cardiolipin also was obtained as a 6.67 mM solution in CHCl3 
from Avanti Polar Lipids and is stored at -20°C upon receipt. MOPS, NaCl, DETAPAC, 
and glycerol were obtained from Sigma-Aldrich and are stored at room temperature. DTT 
was also from Sigma-Aldrich and upon receipt a 500 mM solution is made and stored at -
80°C. TLC plates were purchased from VWR and are stored desiccated at RT. 13x100 mm 
borosilicate glass tubes were obtained from Fisher Scientific. 
 
Buffers 
 
Reaction buffer for β-octylglucoside assay:  
20 mM MOPS, pH 7.2, 50 mM NaCl, 1 mM DTT, 3 mM CaCl2 , 51.24 
mM β-octylglucoside, 1 mM cardiolipin, and 0.2 mM 
diethylenetriaminepentaacetic acid 
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Reaction buffer for Triton X-100 assay: 
20 mM MOPS, pH 7.2, 50 mM NaCl, 1 mM DTT, 3 mM CaCl2 , 1 mM 
cardiolipin, and 0.2 mM diethylenetriaminepentaacetic acid 
 
Experimental Procedures 
 
1. Solubilization of ceramides. 
 
a. β-octylglucoside methods 
 
First described by Bajjalieh and coworkers, this method utilizes the β-octylglucoside as 
the micelle detergent (25). octlyglucoside is nonionic detergent that forms micelles of 27 
molecules each at a critical micellar concentration of 23-25 mM. Micelle solubilization of 
ceramide in this method is carried by sonicating ceramide in reaction buffer. The 
preparation of β-octylglucoside micelles for CERK assay is described below. 
25 mg of cardiolipin is dried under a stream of dry nitrogen gas followed by dissolving 
in 3.333 ml water containing 256 mM β-octylglucoside and 1 mM DETAPAC to obtain a 5 
mM cardiolipin solution.  To prepare the reaction buffer, 160 µl of this solution was mixed 
with MOPS, NaCl, CaCl2 and DTT such that the final concentrations are 20 mM MOPS 
(pH 7.2), 50 mM NaCL, 1 mM DTT, 3 mM CaCl2, 51.24 mM β-Octylglucoside, 1 mM 
Cardiolipin and 0.2 mM DETAPAC. 640 nmol ceramide is dried down under a stream of 
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dry nitrogen gas followed by micellar solubilization in 720 µl of the above reaction buffer. 
A Misonix 3000 probe sonicator with a microtip probe (tip diameter of 3mm) is used in the 
sonication (using three pulses of 1 minute duration with 10 second intervals in between, on 
ice). 180 µl of this mixture is used per reaction as explained below. 
 
b. Triton X-100 method. 
 
First described for CERK by Wijesinghe et al., this method uses the nonionic detergent 
Triton X-100 for the preparation of mixed micelles (Wijesinghe et al., 2005). Triton X-100 
differs from β-octylglucoside in having 140 molecules per micelle and a CMC of 0.24 
mM. The preparation of Triton X-100 mixed micelles containing D-erythro-C16:0 ceramide 
at its Kmb (0.36 mol%) and cardiolipin is described below.  
43.35 nmol ceramide is dried down with 250 nmol cardiolipin under a stream of dry 
Nitrogen gas. 5.75 µmol Triton X-100 in water is then added to the dried lipids such that 
the final volume is 500 µl and the final concentrations are 8.67 µM ceramide, 0.5 mM 
cardiolipin and 11.5 mM Triton. A Misonix 3000 probe sonicator with a microtip probe 
(tip diameter of 3 mm) is used to sonicate this mixture. Sonication is carried out on ice 
using three pulses of 1 minute duration with a 10 second resting interval (on ice) in 
between each pulse.  40 µl of this mixture containing the mixed micelles is added to 140 µl 
of reaction buffer (20 mM MOPS, pH 7.2, 50 mM NaCl, 1 mM DTT, 3 mM CaCl2, and 0.2 
mM diethlenetriaminepentaacetic acid) for a total volume of 180 µl.  
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In both methods, care must be taken to prevent the ceramide solution from heating. This is 
achieved by carrying out the sonication on ice. Also “frothing” of the mixture must be 
avoided at all costs. The mixed micelles, thus prepared, can be kept on ice up to a day. It is 
recommended that they not be stored for longer. 
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Figure 1.5. Surface dilution kinetics for CERK using Triton X-100 mixed micellar 
assay:  Michaelis-Menten curve for D-erythro-C16:0 ceramide assayed at 0.025, 0.05, 0.1, 
0.2, 0.4, 0.6, 0.9, and 1.4 mol%. The graph depicts micromoles of C1P produced per 
minute per milligram of CERK (baculovirus-expressed) versus the mole fraction of 
ceramide to obtain Vmax and Kmb. Data are presented as means SEM and are representative 
of three separate determinations. 
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2. Ceramide Kinase Assay. 
 
Reactions are carried out in 13x100 mm borosilicate glass tubes. 180 µl of micellar 
solubilized ceramide in reaction buffer from either the a or b sections above is used in the 
reaction. Recombinant/purified ceramide kinase is diluted to 0.1 µg/µl in lysis buffer (if 
using unpurified cell lysates from CERK overexpressed cells, the crude lysate is diluted 1 
µg/µl in lysis buffer). 10 µl of the diluted CERK is added to each reaction, mixed by gently 
pipetting up and down and incubated at 37 °C for 10 minutes. The reaction is then started 
by the addition of 10 µl of ATP from a stock solution of 20 mM such that the final 
concentration is 1 mM (the total reaction volume is 200 µl). The mixture is incubated at 
37°C for 15 minutes and the reaction is stopped by the addition of 1.2 ml 1:1 v/v 
CHCl3:MeOH. Thereafter, 500 µl of 1 M KCl in 20 mM MOPS (pH 7.2) is added followed 
by vigorous vortexing and separation of phases by centrifugation at 250xg. 
 
3. Quantification of the C1P produced: 
 
There are three different methods used in the quantification of C1P produced in vitro in 
the above reaction. They are quantification using TLC (Bielawska et al., 2001), 
quantification by direct scintillation counting (Bectas et al., 2003) and quantification using 
mass spectrometry (ESI-LC/MS/MS) (Merrill et al., 2005). The first two methods involve 
labeling a portion of C1P produced using [γ-32P] ATP, and the reaction is started by adding 
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a mixture of labeled and unlabelled ATP such that final concentration in the reaction is 
0.05 µCi and 1 mM ATP. The TLC method, while being time consuming and 
cumbersome, allows for the elimination of any other contaminating lipid species 
(radiolabeled) from contributing to the total radioactivity assayed producing for more 
accurate results. This technique is best suited for instances where tissues levels of active 
ceramide kinase are to be investigated. The direct scintillation counting method is a faster 
method of analyzing CERK activity. However, any other lipid radiolabelled by 
contaminating lipid kinases will also be present. Thus, this method is best suited for 
instances where the enzyme is highly expressed such that contribution from other lipid 
kinases are negligible, or when using purified CERK.  
 
Another method of quantifying CERK activity is ESI LC/MS/MS. The main advantage of 
ESI LC/MS/MS method is the ability to assay C1P levels without using hazardous 
radioactive material. This allows for the reactions to be carried out on any laboratory bench 
without shielding. The high selectivity of the method allows for separation of C1P from 
other lipid phosphates, from the activity of other lipid kinases and lipid substrates. Thus, 
the technique is good for measuring CERK activity in tissues as well. However, in terms of 
sensitivity, the radiolabeled assays are currently superior to mass spectrometric assays.  
 
a) Quantification by thin layer chromatography 
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An aliquot of the organic phase is spotted on a TLC plate, and lipids are separated in 
chloroform/acetone/methanol/acetic acid/water (10:4:3:2:1, v/v). Radioactive bands are 
visualized with a phosphoimager (Bio-Rad), and [32P]-ceramide-1- phosphate is 
quantitated by densitometry or scintillation counting. (See Table 1 for Rf values of various 
C1P species) 
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Table 1.2: Rf Values for Lipid Standards Resolved in Solvent System: Chloroform–
Acetone–Methanol–Acetic Acid–Water (10:4:3:2:1; v/v) (Bielawska et al., 2001) 
 
Standards  RF value  
D-e-C2:0 ceramide phosphate  0.36  
D-e-C6:0 ceramide phosphate  0.49  
D-e-C12:0 ceramide phosphate  0.58  
D-e-C14:0 ceramide phosphate  0.61  
D-e-C16:0/D-e-C18:0 ceramide phosphate  0.63  
D-e-C24:0/D-e-C24:1 ceramide phosphate  0.68  
D-e-C2:0 dihydroceramide phosphate  0.37  
D-e-C6:0 dihydroceramide phosphate  0.53  
D-e-C16:0/D-e-C18:0 dihydroceramide phosphate  0.68  
a-OH-D-e-C6:0 ceramide phosphate  0.40  
C26:0 phytoceramide phosphate  0.63  
a-OH-C24:0 phytoceramide phosphate  0.51  
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b) Quantification by direct scintillation counting. 
 
After the reaction is stopped the organic layer is washed 4 times using 500 µl of 1M 
KCl in 20 mM MOPS (600 µl). The amount of C1P produced is quantified by counting 
100 µl organic phase using a Beckman-Coulter LS 6500 scintillation counter. The presence 
of C1P can be confirmed by TLC as detailed above in section A. 
 
c) Quantification using electron spray ionization liquid chromatography tandem 
mass spectrometry (ESI LC/MS/MS) 
  
To the organic phase obtained from above, a known quantity of internal standard, 
ideally an unnatural C1P (e.g. C12 C1P or C17 C1P) is added. The organic phase is then 
dried, and the residue is brought up in sample buffer (Merrill, et al., 2005). The C1P 
produced can be identified and quantified by MRM using either [M+H]+ (molecular ion) , 
and 264.4 (ceramide) ion pair in the positive ion mode, or [M-H]- (molecular ion) and  78.9 
(phosphite) ion pair, in the negative mode. More information on mass spectrometric 
analysis of CERK can be found in Chapter 4. 
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CHAPTER 2: SUBSTRATE SPECIFICITY AND KINETIC ANALYSIS OF 
HUMAN CERAMIDE KINASE 
 
INTRODUCTION 
 
Understanding of the important role played by sphingolipids in the regulation of 
intracellular processes began with the discovery by Hannun et al (46) of the inhibition of 
protein kinase C (PKC) by sphingosine. Since then ceramides and a number of its 
metabolites have been identified to regulate important cellular processes by regulating the 
activity of key regulatory enzymes (47-54). These include specific serine threonine kinases 
(27, 52), protein phosphatases (55), PKCξ (56), Jun nuclear kinases (JNK) (57, 58), 
mitogen-activated protein kinases (MAPK) (39, 40), phospholipase A2 (PLA2) (59), 
phospholipase D (PLD) (42, 43) and protein kinase B (PKB) (60, 61). 
 
The interconvertable ceramide-derived metabolite, ceramide-1-phosphate (C1P) is 
emerging as an important biological mediator. In mammalian cells, C1P is produced by the 
phosphorylation of ceramides. To date, CERK is the only enzyme known to catalyze this 
reaction in mammals, and CERK was first described as a lipid kinase found in brain 
synaptic vesicles by Bajalieh and coworkers (62). CERK is a calcium-dependent lipid 
kinase specific for phosphorylation of ceramides, but not the structurally related 
diacylglycerol (19, 25, 27). Dressler and Kolesnick also reported the existence of C1P 
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derived from sphingomyelin in human leukemia (HL-60) cells (63). Later, Kolesnick and 
Hemer verified the findings of Bajalieh et al by reporting CERK activity distinguishable 
from diacylglycerol kinase activity in HL-60 cells (27). More recently, Hinkowska-
Galcheva et al and also Rile et al reported the CERK activity in human neutrophils (36, 
64). CERK activity has also been shown in cerebellar granule cells (65) and also in 
epithelial-derived A549 lung carcinoma cells (33).  
 
Increasingly, ceramide-1-phosphate (C1P) is reported in the scientific literature as a 
regulator of intracellular processes. Gomez-Munez et al showed that C1P was a potent 
stimulator of DNA synthesis as well as promoting cell division in rat fibroblasts (37) and 
blocking apoptosis in bone marrow derived macrophages (39). Carpio et al has also shown 
C1P to cause Erk-2 phosphorylation in osteoblastic cells (66). CERK was also implicated 
in the process of phagolyzosome formation during phagocytosis (36). Finally, published 
findings from our laboratory demonstrated for the first time, a role for C1P in signal 
transduction in the inflammatory response (32, 67). Incubation of A549 lung carcinoma 
cells, with Il-1β and A23187 (a Ca+2 ionophore) caused an induction of C1P levels that 
coincided with activation of CERK within the time frame of AA release (67).  Down-
regulation of CERK by RNA interference technology caused a concomitant down-
regulation of AA release in response to IL-1β, ATP and A23187.  In the presence of 
excogenous C1P however, CERK down-regulation had no effect upon the agonist-induced 
AA release. Further studies also disclosed that C1P interacts with the CaLB/C2 domain of 
cPLA2, acting as a positive allosteric activator of cPLA2 and enhancing the interaction of 
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the enzyme with phosphatidylcholine (34). These findings established a role for CERK and 
C1P in the inflammatory pathway. Therefore, with the loss of Vioxx and Bextra as 
therapeutics for inflammation, the characterization of other mediators of inflammation 
such as CERK is warranted. 
 
In this study, we examined the structural requirements within the ceramide molecule 
necessary for recognition and substrate utilization by human CERK. The results disclose 
that even slight modifications to the sphingoid backbone greatly decrease the ability of the 
lipid to identify its substrate and to catalyze the reaction. Thus, the presented study shows a 
high degree of specificity for ceramide by CERK, and identifies key features for the 
development of sphingoid-based inhibitors of the enzyme. 
  
EXPERIMENTAL PROCEDURES 
 
Materials: Serinol and all general chemicals were purchased from Aldrich. 
Phytosphingosine (2S, 3S, 4R), D-erythro-C24:0, C24:1 were purchased from Avanti. D-
erythro-C16 ceramide and various structural analogs were obtained from the Lipidomics 
Core at the Medical University of South Carolina synthesized as previously described (68-
72). All lipids were quality controlled by 1H-NMR spectra, recorded using a Bruker 
AVANCE 500 MHz spectrometer equipped with Oxford Narrow Bore Magnet. Chemical 
shifts are given in parts per million (ppm) downfield from tetramethylsilane as internal 
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standard and the listed J values are in Hz. Mass spectral data were obtained in positive ion 
electrospray ionization (ESI) mode on a Finnigan LCQ ion trap mass spectrometer. 
Samples were infused in methanol solution with an ESI voltage of 4.5 kV and capillary 
temperature of 200 oC. The purity of all synthesized lipids was >95% as estimated by TLC 
and 1H-NMR analysis.  
 
Recombinant expression of CERK using baculovirus: Recombinant human CERK 
(hCERK) was expressed in Sf9 cells with a 6XHis-tag using a baculovirus expression 
system and purified using a modified protocol as previously described (73, 74). Briefly, 
Sf9 cells were grown in suspension culture and infected with high titer recombinant 
baculovirus at a multiplicity of infection of 1.0 and 72 hours post-infection. The cells were 
then harvested and the cell paste was re-suspended in a 10 x cell paste volume lysis buffer 
(10mM MOPS pH 7.2, 150 mM KCl, 10%glycerol, 0.5% Triton, 0.01 mg/ml leupeptin, 
0.01 mg/ml aprotinin, 0.005 mg/ml pepstatin, 1mM PMSF). The cells were broken by 10 
strokes with a dounce homogenizer. The cell lysate was clarified by centrifugation at 
16000xg for 45 mins at 40C. The soluble supernatant was batch bound to 100ml Ni-NTA 
superflow resin for 1.5 hours at 40C with nutation. The column was washed first, with Ni-
NTA wash buffer (10mM MOPS pH 7.2, 150 mM KCl, 10%glycerol) and then with 
19.5mM imidazole at a rate of 4ml/min until A280 baseline absorbance. The column was 
eluted with a step elution to 250 mM imidazole in NI-NTA wash buffer (10mM MOPS pH 
7.2, 150 mM KCl, 10%glycerol, 250mM imidazole) at 5ml/min. The fractions were 
analyzed by SDS-PAGE and fractions containing significant amounts of cPLA2α were 
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pooled and dialyzed against storage buffer (10 mM Tris pH 7.2, 0.1 M NaCl, 2mM EGTA, 
50% glycerol, 1mM DTT). The dialyzed material was then centrifuged at 39,000xg for 30 
mins to remove precipitation and aliquoted into 10 ml fractions. Recombinant CERK was 
assayed at 70% purity by coomassie stain, and retained all of the characteristics (eg. Ca+2 
sensitivity, pH optimum, etc.) as hCERK overexpressed in mammalian cells (19).  
 
Recombinant expression of CERK in mammalian cells: Recombinant CERK was 
expressed in HeLa cells by transfecting the plasmid construct (hCERK in pcDNA3.1 His 
TOPO®) using Effectene reagent (Qiagen Corp.) following the standard procedure. 
Briefly, HeLa cells are plated at 40 to 50% confluency in 150 x 15 mm tissue culture 
dishes 24 hours prior to transfection. Cells are transfected with 6 μg of plasmid under 
conditions specified by the manufacture. After 24 hours, the cells were harvested and the 
crude HeLa extracts were obtained by sonicating in lysis buffer (20mM MOPS, 2mM 
EGTA,0.5 mM DTT with added Sigma® P-8340 protease inhibitor cocktail at 1/250 
dilution). 10 µg protein of the crude extract was used per assay.  
 
Cell Culture: HeLa cells are cultured in DMEM with L-glutamine supplemented with 10% 
fetal bovine serum and 2% penicillin/streptomycin. Incubation conditions are 5%CO2, 
370C, and 95% humidity.  
 
 
Ceramide Kinase Assays 
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a)β-Octylglucoside mixed micellar assay: 160 nmol ceramide were micellar solubilized by 
sonication in 180 ul of reaction buffer (20 mM MOPS (pH 7.2), 50 mM NaCL, 1 mM 
DTT, 3 mM CaCl2, 51.24 mM β-Octylglucoside, 1 mM Cardiolipin , 0.2 mM DETAPAC). 
10μg of crude human CERK (crude lysate of hCERK overexpressed in HeLa cells) or 
0.9µg of baculovirus expressed CERK was added per reaction and incubated at 370C for 5 
minutes. The reaction was started by adding 11μl of ATP (1μl 32P ATP (10μCi/μl) + 10 
μl 20 mM ATP in 100 mM MgCl2). All reactions were carried out in triplicates and with 
D-e-C16 ceramide as a positive control. The reaction was allowed to continue at 370C for 
40 minutes, and stopped by the addition of 1.2 ml 1:1CHCl3:MeOH followed by 500 μl of 
1M KCl in 20 mM MOPS. The mixture was then vortexed and phases separated by 
centrifugation at 650xg for 5 mins. As previously described (75), the organic phase was 
washed thrice with 500 μl aliquots of 1M KCL and 100 μl of the organic phase was 
counted directly. All results (as to substrate utilization) obtained with the Triton X-100 
based assay (see below) were verified with this previously described CERK assay (43). 
 
b) Surface dilution assay with Triton X-100 mixed micelles: Briefly, 0.003, 0.006, 0.012, 
0.024, 0.048, 0.072, 0.109, 0.170 mM ceramide solutions were sonicated with 11.5 mM 
Triton X-100® and 0.5 mM cardiolipin to obtain 0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.9, and 1.4 
mol% ceramide solutions. 40µl each of these solutions were used per 200 µl reaction 
containing 20 mM MOPS (pH 7.2), 50 mM NaCL, 1mM DTT, 3 mM CaCl2, and 0.2 mM 
DETAPAC. 0.9µg of baculovirus expressed or 10µg of crude hCERK (crude lysate of 
hCERK overexpressed in HeLa cells) was used per reaction. The reaction was started by 
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adding 11μl of ATP (1μl λ32P ATP (10μCi/μl) + 10 μl 20 mM ATP in 100 mM MgCl2). 
All reactions were carried out in triplicates. The reaction was incubated at 370C for 15 
minutes and stopped by the addition of 1.2 ml 1:1CHCl3:MeOH. The organic phase was 
washed four times with 500 μl of 1M KCl in 20 mM MOPS. The mixture was then 
vortexed and phases separated by centrifugation at 650xg for 5 mins. as previously 
described (75), The amount of 32P-C1P produced was quantified as previously described 
(75) and confirmed by TLC as previously described (76). 
 
Data analysis: Data analysis was done using Enzyme Kinetics Module™ 1.1 together with 
SigmaPlot version 8.02A. Mole fraction of ceramide was plotted against reaction velocity 
(µmol of C1P produced/min/mg protein) to obtain Kmb and Vmax. The data obtained is the 
mean of triplicate data sets +/-standard error. Two way ANOVA was performed using 
Microsoft Excel. 
 
RESULTS 
 
Previously, CERK was shown only to phosphorylate ceramides and not the closely related 
lipids, diacylglycerol and sphingosine (27). To determine the molecular basis of the 
interaction between CERK and its substrate, ceramide, our laboratory focused on key 
features in the ceramide molecule required for substrate recognition and specificity. These 
include the stereochemistry at the C2, C3, C4, and C5-positions, the requirement of the 
acyl chain length, the effect of the functional groups in the sphingoid-backbone, the 
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requirement of the secondary amide bond, and the requirement of the primary and 
secondary hydroxyl-groups (Figure 2.1). Additionally, the saturation, desaturation, 
configuraion, and hydroxylation of the natural trans C4-C5 double bond and the role of the 
alkyl chain of the sphingoid-backbone were also investigated (Figure 2.1). The data 
presented in this manuscript is from the CERK assay utilizing mixed micelles of Triton X-
100. The previously described assay for CERK was used to verify these results (data not 
shown) (43). 
 
Also of note, Vmax/Km is used in these studies as a measure of the relative rates of 
enzymatic reactions for different substrates under identical conditions. Therefore, Vmax/Km 
is a measure of the specificity of an enzyme to different substrates. A statistically 
significant difference in Vmax/Km is generally considered to denote an actual difference in 
substrate specificity. In this study, we utilized this parameter to investigate the differences 
in substrate specificities of CERK, and all differences in substrate specificity mentioned 
hereafter are statistically relevant. 
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Figure 2.1.  The investigated structural features of ceramide. 
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Stereochemistry. 
 
There are two asymmetrical carbon atoms within the ceramide molecule, and thus, four 
stereoisomers are possible. D-erythro-C16 ceramide (2S, 3R) is the naturally occurring 
configuration, with L-erythro-C16 ceramide (2R, 3S) being its enantiomer. Additionally, 
enantiomeric pairs of the threo-diastereoisomers can be formed, L-threo (2S, 3S) and D-
threo (2R, 3R). In this study only the D-erythro configuration of ceramide was converted 
to ceramide-1-phosphate. CERK demonstrated no activity towards the other stereoisomers 
of ceramide. Thus, CERK only phosphorylates the naturally occurring D-erythro 
ceramides (Table 1). 
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Table 2.1 
Km and Vmax of all the ceramides and ceramide analogs examined for CERK  
(baculovirus expressed). 
Values represent the mean from three separate determinations 
Ceramide tested Kmb Vmax Vmax/Km 
 mol fraction 
(µM) 
µmolC1P/min/mg 
protein 
 
D-e-C2:0-Cer NS NS NS 
D-e-C4:0-Cer NS NS NS 
D-e-C6:0-Cer 0.1109  (299.36) 0.4456 4.0180 
D-e-C8:0-Cer 0.0657  (168.77) 0.6843 10.42 
D-e-C10:0-Cer 0.0186    (45.49) 0.4408 23.75 
D-e-C12:0-Cer 0.0086    (20.82) 0.3357 39.11 
D-e-C14:0-Cer 0.0026      (6.26) 0.1590 60.46 
D-e-C16:0-Cer 0.0036      (8.67) 0.1882 52.53 
D-e-C16:0 dehydro-Cer 0.0018      (4.33) 0.0338 18.70 
D-e-C16:0 dihydro-Cer 0.0034      (8.19) 0.0723 21.33 
D-e-C16:0 -cis-Cer 0.0506  (127.91) 0.5485 10.85 
D-e-C16:0 (R)-α-hydroxy Cer 0.0026      (6.26) 0.0294 11.14 
D-e-C16:0 (S)-α-hydroxy Cer 0.0030      (7.22) 0.0070 2.34 
D-e-C18:0-Cer 0.0028      (6.74) 0.1557 56.56 
D-e-C18:0 phytoceramide 0.0023      (5.53) 0.0451 19.82 
D-e-C24:0-Cer 0.0033      (7.95) 0.1626 49.29 
D-e-C24:1-Cer 0.0068     (16.43) 0.3059 44.93 
1-0-methyl C16:0 -Cer  NS NS NS 
3-0-methyl C16:0 -Cer 0.0049     (11.82) 0.0247 5.04 
D-e-C16 Urea Cer 0.0008      (1.92) 0.0097 11.54 
L-e-C16 Urea Cer NS NS NS 
N-methyl C16:0 -Cer NS NS NS 
D-t- C16:0-Cer NS NS NS 
L-e- C16:0-Cer NS NS NS 
L-t- C16:0-Cer NS NS NS 
D-t-C6:0-Cer NS NS NS 
L-e-C6:0-Cer NS NS NS 
L-t-C6:0-Cer NS NS NS 
(R)α-hydroxy-C16-1,3-
Acetoinide of Ceramide 
NS NS NS 
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(1S, 2S) B13 NS NS NS 
(1R, 2R) B13 NS NS NS 
N-palmitoyl-serinol (C16 
Serinol) 
NS NS NS 
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The effect of the chain length of the acyl chain. 
 
Since sphingosine has been shown not to be a substrate for CERK, we examined various 
acyl chain lengths of ceramide to determine the minimum size for substrate recognition. 
We found no statistically significant effects on substrate specificity for chain lengths ≥C12:0 
(Figure 2.2A, 2.21B, and Table 2.1). With decreasing acyl chain lengths, however (<C12:0), 
CERK showed a proportionate, statistically significant, decrease in enzymatic activity 
indicated by increasing Kmb and decreasing specificity (Vmax/Kmb). Both C2- and C4-
ceramide were found not to be substrates for CERK. Thus, a minimum of 14 carbons are 
required for full recognition of ceramide as a substrate by CERK, and ceramides with an 
acyl chain <6 carbons are not recognized as substrates. These data indicate that ceramides 
with chain lengths observed to occur in cells are preferred substrates of CERK (45-47). 
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Figure 2.2 Panel A:  Michaelis-Menton curves for ceramides of different acyl chain 
lengths. Specificity of ceramides of different acyl chain lengths were assayed at 0.025, 
0.05, 0.1, 0.2, 0.4, 0.6, 0.9, and 1.4 mol% as described in materials and methods. The 
graph depicts the µmoles of C1P produced per minute per mg of CERK (baculovirus 
expressed) versus mol fraction of ceramide to obtain Vmax and the intrafacial Michaelis-
Menton constant (Kmb). Data are presented as mean ± standard error and are representative 
of three separate determinations. D-e-C8:0 ceramide (●), D-e-C10:0 ceramide (○), D-e-C12:0 
ceramide(▼), D-e-C14:0 ceramide(  ), D-e-C16:0 ceramide (■), D-e-C18:0 ceramide (□), D-e-
C24:0 ceramide (♦). Note: for both C6:0 (not depicted) and C8:0, a higher range 
(concentration of ceramide) was utilized to establish Kmb and Vmax due to their poor 
substrate specificity constant (higher range concentrations not depicted). 
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Figure 2.2 Panel B: Specificity constants for the different acyl chain lengths of 
ceramide. Data presented are the specificity constants (Vmax/Kmb) for D-e-C8:0, C10:0, C12:0, 
C14:0, C16:0, C18:0 and D-e-C24:0 ceramide ± standard error. Data are representative of three 
separate determinations. Significance of the differences in specificity constants when 
compared to D-e-C16:0 ceramide was examined by two way ANOVA, p <0.1(  ), p <0.01  
(    ), p <0.005 (       ). 
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Saturation state of the acyl chain. 
 
The main forms of ceramide found in mammalian cells are D-e-C16:0 ceramide and D-e-
C24:1 ceramide (77-79). In this study, we examined whether CERK possessed any selective 
characteristics for saturated or unsaturated acyl chains of ceramide, using D-e-C24:0 
ceramide and D-e-C24:1 ceramide (Figure 2.3 and Table 2.1). Although the saturated 
ceramide showed a lower Km compared to the unsaturated ceramide, this was accompanied 
by a proportionate change in the Vmax. As a result, no statistically significant difference 
was observed in the specificity constant (Vmax/Kmb). Thus, differences in the Km and Vmax 
may be attributed to the higher solubility of the monounsaturated form. A similar pattern 
was observed between D-e-C18:0 ceramide D-e-C18:1 ceramide (data not shown). Thus 
CERK seem to equally recognize ceramides containing both saturated and unsaturated 
fatty acyl chains. 
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Figure 2.3: The saturation state of the acyl chain does not affect the substrate 
specificity of CERK. Ceramides with saturated (C24:0) and unsaturated (C24:1) acyl chains 
were assayed at 0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.9, and 1.4 mol% as described in materials 
and methods. The graph depicts µmoles of C1P produced per minute per mg of CERK 
(baculovirus expressed) versus mol fraction of ceramide to obtain Vmax and the intrafacial 
Michaelis-Menton constant (Kmb). Data are presented as mean ± standard error and are 
representative of three separate determinations. D-e-C24:0 ceramide (●), D-e-C24:1 ceramide 
(○). Inset: Specificity constants for D-e-C24:0, and D-e-C24:1 ceramide. Data presented 
are the specificity constants (Vmax/Kmb) for D-e-C24:0 and D-e-C24:1 ceramide ± standard 
error. Data are representative of three separate determinations. 
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Effect of α hydroxylated fatty acids. 
 
Ceramidase, another ceramide utilizing enzyme, is capable of utilizing ceramides with α 
hydroxy fatty acids as a substrate (80). Therefore, the ability of CERK to utilize α 
hydroxylated ceramides was also investigated (Table 2.1). CERK was able to 
phosphorylate both R and S, D-e-C16:0- α hydroxyl ceramides, but demonstrated a lower 
specificity constant compared to the naturally occurring long chain ceramides (Table 2.1). 
Thus, CERK possesses the ability to phosphorylate α hydroxylated ceramides, and an α 
hydroxylated C1P may exist in cells. 
 
Sphingoid Moiety 
 
The sphingoid-backbone modifications shown in figure 2.1 were introduced into the 
ceramide molecule. First, the requirement for the 4-5 double bond within the sphingoid 
moiety was examined. Saturation of the 4-5 double bond produces D-erythro-
dihydroceramide, an anabolic precursor of ceramide, which has been shown to be 
biologically inactive in cells (70). CERK showed significantly reduced specificity 
(p<0.005) towards the dihydroceramides as compared to ceramide (Figure 2.4A and Table 
2.1). 
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To further examine the necessity of the 4-5 double bond of ceramide for use as a substrate 
for CERK, this moiety was further unsaturated to D-erythro-dehydro-C16 ceramide 
producing a triple bond between the 4 and 5 carbons of the sphingoid backbone. This 
compound also showed a decreased specificity (p<0.005) compared to the natural 
ceramides (Figure 2.4A and Table 2.1). Since natural ceramide has the 4-5 double bond in 
the trans-configuration, the nature of the 4-5 double bond was further examined by 
modifying the configuration from trans to cis. CERK also showed a significant decrease 
(p<0.005) in specificity for this substrate as well (Figure 2.4A and Table 2.1).  
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Figure 2.4: Alteration of the 4,5 double bond of ceramide significantly affects the 
recognition of ceramide by CERK. Panel A. Michaelis-Menton curves for C16 
ceramides with different 4,5 bonds.  D-e-C16:0 trans, C16:0 cis, C16:0 dehydro, C16:0 
dihydro ceramides were assayed at 0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.9, and 1.4 mol% as 
described in materials and methods. The graph depicts the µmoles of C1P produced per 
minute per mg of CERK (baculovirus expressed) versus mol fraction of ceramide to obtain 
Vmax and the intrafacial Michaelis-Menton constant (Kmb). Data are presented as mean ± 
standard error and are representative of three separate determinations. D-e-C16:0 ceramide 
(●), D-e-C16:0 dehydro ceramide (○), D-e-C16:0 dihydro ceramide (▼), D-e-C16:0 cis 
ceramide (♦). 
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Recently, phytoceramides were described in mammalian cells, (81-83) thus, the use of 
phytoceramides (4-hydroxy-dihydroceramides) as substrates for CERK were also 
investigated. C18:0-phytoceramide showed a decreased specificity constant (p<0.005) when 
compared against C18:0 ceramide (Figure 2.4B and Table 2.1). Thus, these data demonstrate 
that CERK has a marked preference for the saturation level and the trans-orientation of 
double bond at the 4-5 position. 
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Figure 2.4 Panel B: Michaelis-Menton curves for C18:0 ceramide and C18:0 
phytoceramide. D-e-18:0 ceramide and D-e-C18:0 phytoceramide were assayed at 0.025, 
0.05, 0.1, 0.2, 0.4, 0.6, 0.9, and 1.4 mol% as described in materials and methods. The 
graph depicts the µmoles of C1P produced per minute per mg of CERK (baculovirus 
expressed) versus mol fraction of ceramide to obtain Vmax and the intrafacial Michaelis-
Menton constant (Kmb). Data are presented as mean ± standard error and are representative 
of three separate determinations. D-e-C18:0 ceramide (●), D-e-C18:0 phytoceramide (○). 
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Figure 2.4 Panel C. Specificity constants for the ceramides with different 4,5 bonds. 
Data presented are the specificity constants (Vmax/Kmb) for D-e-C16:0 trans, C16:0 cis, C16:0 
dehydro, C16:0 dihydro, C18:0 trans ceramides and C18:0 phtyoceramides ± standard error. 
Data are representative of three separate determinations. Significance of the differences in 
specificity constants when compared to D-e-C16:0 ceramide (for D-e-C16:0 dehydro, dihydro 
and cis ceramide) and D-e-C18:0 (for D-e-C18:0 phytoceramide) were examined by two way 
ANOVA, p <0.005 (       ). 
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The necessity of other sphingoid structural features were also examined. Clearly, from 
other published findings, the free sphingoid bases, sphingosine and dihydrosphingosine, 
are not substrates of CERK (19). The question remains, however, if the sphingoid-base 
chain is necessary for the recognition of ceramide as a substrate for CERK. To this end, 
serinol ceramide (a ceramide analog with a truncated sphingosine-backbone containing 
only the C1-C3 part from serine) was synthesized and tested in vitro (69). The results show 
that N-hexadecanoyl-serinol (serinol ceramide) was not a substrate (Table 1). The 
structural features of the sphingoid moiety were further investigated by replacing the 
sphingoid alkenyl chain with an aromatic phenyl group producing two enantiomers, 
(1R,2R)-2-(N-Myristoylamino)-1-(4’-nitrophenyl)-1,3-propandiol (1R,2R-B13) and 
(1S,2S)-2-(N-Myristoylamino)-1-(4’-nitrophenyl)-1,3-propandiol (1S,2S-B13). Neither of 
these compounds were substrates for CERK (Table 1). Therefore, the sphingosine chain is 
necessary for CERK to recognize ceramide as a substrate. 
 
Amide group 
 
To determine the importance of the secondary amide group –NHCO- in the ceramide 
structure, we synthesized urea-isosters of ceramide bearing –NHCONH- instead of the -
NHCO- group, producing two enantiomers, 2S,3R (i.e. D-erythro) and 2R,3S (i.e. L-
erythro)-urea-C16 ceramide. D-erythro-urea-C16 ceramide was a substrate for CERK, but 
demonstrated significantly lower specificity (p<0.005) compared to the naturally occurring 
ceramides (Figure 2.5 and Table 2.1). Also, similar to L-erythro-C16 ceramide, L-erythro-
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urea-C16 ceramide was not a substrate (Table 2.1). These results indicate that the N-acyl-
amide bond is required for the complete recognition of the substrate by CERK. Next, the 
role of the hydrogen atom from the amide bond –NHCO- was examined using N-methyl-
C16 ceramide as a model. This compound was also not a substrate of CERK (Table 1), 
demonstrating the necessity of the free hydrogen in the secondary amide group for 
recognition by CERK. 
 
Primary and Secondary Hydroxyl-groups 
 
The necessity of the free primary and secondary hydroxyl groups of the ceramide molecule 
was examined by using 1-O-methyl-C16 ceramide and 3-O-methyl-C16 ceramide (Figure 
2.1). Methylation of the primary hydroxyl group completely eradicated the ability of 
CERK to phosphorylate ceramide. Methylation of the secondary hydroxyl group showed 
dramatically decreased specificity (p<0.005) for the substrate by CERK (Figure 2.5 and 
Table 2.1). To further investigate the importance of the primary and the secondary 
hydroxyl groups, the ability of CERK to phosphorylate C16:0-1,3-acetoinide was tested. 
This compound was also not a substrate of CERK (Table 2.1). These data confirm that 
primary hydroxyl group is the site of phosphorylation by CERK and that the secondary 
hydroxyl group although not involved in direct phosphorylation, is still important for 
substrate recognition. 
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Figure 2.5. The secondary amide and the secondary hydroxyl groups of ceramide are 
important for substrate recognition by CERK.  Panel A. Michaelis-Menton curves for 
C16:0, C16:0 -3-O-methyl, and C16:0 urea ceramide. D-e-C16:0, C16:0-3-O- methyl, and C16:0 
urea ceramides were assayed at 0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.9, and 1.4 mol% as 
described in materials and methods. The graph depicts the µmoles of C1P produced per 
minute per mg of CERK (baculovirus expressed) versus mol fraction of ceramide to obtain 
Vmax and the intrafacial Michaelis-Menton constant (Kmb). Data are presented as mean ± 
standard error and are representative of three separate determinations. D-e-C16:0 
ceramide(●), D-e-C16:0-3-O- methyl ceramide (○), and D-e-C16:0 urea ceramide (▼). 
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Figure 2.5. Panel B. Comparative specificities of CERK towards modifications to the 
secondary amide and hydroxyl group.  Data presented are the specificity constants 
(Vmax/Kmb) for C16:0, C16:0-3-O- methyl, and C16:0 urea ceramides ± standard error. Data are 
representative of three separate determinations. Significance of the differences in 
specificity constants when compared to D-e-C16:0 ceramide was examined by two way 
ANOVA, p <0.005 (       ). 
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DISCUSSION 
 
In this study, we demonstrate the strict structural requirements of ceramide for recognition 
as a substrate by CERK. The understanding of this action of recognition is important for 
several reasons. First, these studies begin to identify features for ceramide-based inhibitors 
of CERK, allowing for the possible designing of new anti inflammatory compounds. 
Second, these studies add to our knowledge of the biochemical mechanisms of CERK and 
sphingolipid enzymes in general. Lastly, these studies further disclose that this interaction 
between ceramide and CERK has implications for the physiological regulation of the 
enzyme.   
 
Previously published kinetic studies on CERK were accomplished using a bulk dilution 
technique and mixed micelles of β-OG (40). In this regard, molecular modeling studies 
show β-OG to have an irregular surface (42), thus, all the substrate in the micelle is not 
presented equally to the enzyme. Furthermore, as ceramides are found in membranes, the 
true kinetic behavior of the enzyme can only be studied using a model that takes into 
account both bulk and surface diffusion of the enzyme. Therefore, in this study, surface 
dilution kinetics (34, 84) utilizing Triton X-100 mixed micelles were used to characterize 
the substrate specificity of CERK. Triton X-100 micelles provide several advantages. First, 
they provide an inert surface for CERK containing an average of 140 molecules/micelle. 
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Second, the size of the micelles are relatively independent of ionic strength and 
temperature within the physiological range (43-45, 85). Lastly, mixed micelles up to 20 
mol % phospholipids are similar in structure to pure Triton X-100 micelles, but 
proportionally larger (43, 45, 85), and pure Triton X-100 micelles do not co-exist with 
mixed micelles. Therefore, the new Triton X-100 based assay presented in these studies 
provided an excellent means of studying the kinetics of CERK. 
 
Using this assay, the presented study corroborates the findings of Sugiura et al (86) in that, 
C2 ceramide is not a substrate of CERK. In addition C4 ceramide was also found not to be 
phosphorylated by CERK, thus greater than a C4 acyl chain is required for recognition by 
CERK. These previous studies by Sugiura and co-workers also showed C8 and C6 
ceramides to be good substrates of CERK based on activity at fixed concentrations, which 
would be a reflection of the differences in their Vmax (19). In contrast, the Michaelis-
Menton constant, Kmb, was taken into account in this study as well as Vmax to study the 
substrate specificity (Vmax/Kmb), since this is a more accurate indication in comparing the 
affinity of an enzyme to different substrates. Therefore, although the Vmax of C6 and C8 
ceramides are in general greater than long chain ceramides, the ratio Vmax : Km is 
dramatically lower by comparison.  Sugiura et al (86) also reported that C8 
dihydroceramide was a good substrate for CERK with a comparable Vmax to long chain 
ceramides. Our study using naturally occurring D-e-C16 ceramides show saturation of the 
4,5 double bond induces a significant decrease in substrate preference by CERK.  
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Therefore, these studies demonstrate the importance of examining the Km and specificity 
constant for determining substrate preference for lipid kinases.  
 
The presented study also examined the substrate preference of CERK in depth. As alluded 
to above, the presence of the 4,5 double bond of the sphingoid moiety is an important 
feature for recognition by CERK as dehydro, dihydro, and phytoceramide all showed 
decreased substrate specificity. In addition, the natural trans configuration of the double 
bond is also important as the cis configuration showed greatly reduced specificity. Thus, 
the 4,5 double bond of the sphingoid moiety is likely an important contact point for the 
substrate with CERK. Furthermore, results disclosed the importance of the sphingoid alkyl 
chain as replacement of the alkyl chain with an aromatic phenyl group caused a dramatic 
loss in phosphorylation. Thus, the sphingoid moieties of ceramide are essential for 
substrate recognition and phosphorylation by CERK explaining why CERK 
phosphorylates ceramide and not the closely related glycerol lipids like DAG. For the 
purpose of designing pharmacologic inhibitors of CERK based on sphingoid moieties, 
these required features of ceramide that affect the substrate specificities of CERK should 
be taken into account. For example, at least a six carbon acyl chain should be utilized as a 
shorter acyl chain length is not recognized by CERK. To this end, unpublished findings 
from our laboratory demonstrate that C2 ceramide is not an inhibitor of CERK. 
 
The structural requirements for substrate recognition by CERK also appear different from 
other ceramide-utilizing enzymes. CERK showed very high stereospecificity using only 
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the D-erythro ceramides as substrates. In contrast, glucosylceramide synthase (GCS) can 
use both D-erythro and L-erythro isoforms (87), while Stoffel et al. (88) reported that 
sphingomyelin synthase (SMS) prefers L-threo isoform over the D-erythro. In terms of 
chain length, neutral ceramidase (80) shows a marked preference for long chain and 
unsaturated ceramides. In contrast, CERK does not discriminate between a saturated and 
unsaturated ceramide. In addition, the phytoceramides, 4,5-cis-ceramide, and 3-O-methyl 
ceramides were not substrates for ceramidase (80). However, these are substrates for 
CERK although the substrate specificity is greatly reduced. CERK does show some 
similarities to neutral ceramidase in utilizing only the D-erythro isoform as a substrate and 
demonstrating decreased specificity for dihydro ceramides. Furthermore, as in the case of 
neutral ceramidase, CERK does not recognize N-methyl ceramides as substrates. Thus, the 
recognition of ceramide as a substrate by CERK is more similar to the substrate 
preferences of ceramidase than to other ceramide metabolizing enzymes like GCS and 
SMS. However there are still clear differences between the substrate preferences of CERK 
and ceramidase making CERK unique within the ceramide metabolizing enzymes. 
 
These studies also suggest a mechanism for the intracellular utilization of ceramide by 
CERK. Unpublished findings from our lab demonstrate that the major form of C1P found 
in A549, HeLa, and J774.1 macrophage cells is D-e-C16:0 ceramide. As CERK does not 
discriminate among the long chain ceramides, the prevalence of particular forms of C1P is 
likely due to substrate availability. Furthermore, a recent report by Baumruker (89) and 
coworkers localizes CERK to the Golgi apparatus, and ceramide transport protein (CERT), 
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the enzyme responsible for actively transporting ceramide to the Golgi apparatus 
demonstrates a preference for the D-e-C16 ceramide (90). These suggest that CERK 
produces predominantly D-e-C16:0 C1P due to substrate availability regulated by the 
transport of ceramides to the Golgi apparatus by CERT. 
 
In conclusion, CERK shows very high specificity towards the naturally occurring 
ceramides. This high specificity allows the enzyme to distinguish between ceramides and 
other structurally related compounds like sphingosine and diacylglycerol. Furthermore, 
substrate preference cannot explain the predominance of D-e-C16:0 C1P in cells, and CERK 
demonstrates different requirements for sphingoid moieties than other sphingolipid 
enzymes. These structural features identified as essential for substrate recognition can now 
be used as a basis for the rational designing of inhibitors to CERK. Since CERK has an 
established role in the inflammatory pathway as an upstream activator of cPLA2α, 
inhibitors of CERK may become a new generation of anti-inflammatory drugs. With the 
COX-2 inhibitors, Vioxx (4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one) and 
Bextra (4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide), now withdrawn from 
the pharmaceutical market, the designing of novel anti-inflammatory compounds are a high 
priority as therapeutics for disorders like arthritis, asthma, multiple sclerosis and 
Alzheimer’s disease. 
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CHAPTER 3:  THE CHAIN LENGTH SPECIFICITY FOR THE ACTIVATION OF 
GROUP IV CYTOSOLIC PHOSPHOLIPASE A2 BY CERAMIDE-1-PHOSPHATE.  
 
INTRODUCTION  
 
The first report of a biological effect for C1P was by Brindley and coworkers (37), which 
demonstrated that short chain (not naturally found in cells) C1P induced DNA synthesis in 
Rat-1 fibroblasts (37). Later, treatment of T17 fibroblasts with long chain, natural 
ceramide-1-phosphate was also demonstrated to induce a potent increase in DNA synthesis 
(38) and the levels of proliferating nuclear antigen. Following this line of research, a recent 
report demonstrated that C1P prevented programmed cell death in bone marrow-derived 
macrophages (BMDMs) after withdrawal of macrophage colony-stimulating factor (M-
CSF) (91). Treatment of these cells with C1P effectively blocked the activation of caspases 
and prevented DNA fragmentation upon serum removal. In the same study, they also 
demonstrated that C1P treatment inhibited ceramide generation from acid 
sphingomyelinase (A-SMase). Lastly, A-SMase was shown to be a direct target of C1P 
inducing inhibition of this enzyme (39).  
 
In the last few years, a number of reports have continued to demonstrate distinct biological 
mechanisms regulated by the sphingolipid, C1P, and the enzyme responsible for its 
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synthesis, ceramide kinase (CERK). For example, Shayman and coworkers demonstrated 
that CERK was activated in the context of phagocytosis in neutrophils after challenging the 
cells with formyl peptide and antibody-coated erythrocytes (FMLP/EIgG) (36). Thus, these 
data demonstrated that C1P may play a distinct role in membrane fusion possibly 
explaining the early finding that high levels of C1P are found in synaptic vesicles (25). Our 
laboratory has also demonstrated a biological function for C1P as a direct activator of 
cPLA2α through interaction with the C2/CaLB domain (32). These results coupled with the 
previous findings that CERK/C1P pathway is required for cPLA2α activation in response 
to calcium ionophore and cytokines (67) demonstrated that C1P was a “missing link” in 
the eicosanoid synthetic pathway. A role for CERK and its product, C1P, in a separate 
pathway of allergic/inflammatory signaling has also been reported in mast cells. Igarashi 
and coworkers demonstrated that treatment of RBL-2H3 cells or overexpression of CERK 
in these cells enhanced the degranulation induced by A23187 (35).  
 
While there is a growing list of biological functions attributed to C1P, it is unclear whether 
an effect observed for different chain lengths of C1P can be extrapolated to all biological 
observations. In this regard, many chain lengths of C1P have been utilized exogenously to 
examine biological effects. For example, short chain C1Ps are ideal candidates for 
studying the biology of C1P as their higher solubility allows for relatively easy delivery to 
target cells. In this regard, Högback et al (2003) and Tornquist et al (2004) showed that 
C2-C1P induced an increase in the intracellular Ca+2 levels in FRTL5 cells and GH4C1 rat 
pituitary cells. Using the same lipid, Graf et al (2006) showed a correlation between 
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apoptosis and enhanced C2-C1P formation upon C2-ceramide treatment of CERK 
overexpressing COS cells. C2, C8 and long chain C1P have also been demonstrated to 
cause 3H thymidine incorporation into DNA (37, 38). Our laboratory using the naturally 
occurring C16:0 and C18:1 C1P showed the lipid is a co-factor in the activation of cPLA2α 
and synthesis of eicosanoids (32, 67). Since eicosanoids pathways have roles in calcium 
homeostasis (92, 93), cell survival (94), apoptosis (95), and cell growth (95), the question 
remains whether these biologies reported for C1P can be attributed to simply cPLA2α 
activation. In addition, a recent paper by Bornancin and co-workers demonstrated that 
using dodecane to deliver phospholipids induced eicosanoid synthesis and loss of cell 
viability in a non-specific manner (96) casting doubts on the validity of this well-
established method of lipid delivery.  
 
In this paper, we show that while the ethanol/dodecane system successfully delivers all 
chain lengths of C1P to cells, not all chain lengths activate cPLA2α in vitro and in cells. 
Thus, certain biologies attributed to C2-C1P are not via activation of cPLA2α.  In addition, 
we also demonstrate that at low concentrations, C1P exerts biological effects that are 
specific, non-toxic, and distinct from other structurally similar lipid molecules as well as 
the delivery medium. Therefore, this study shows that the alcohol/dodecane delivery 
system can be utilized to study lipid-specific effects if proper controls and appropriate lipid 
concentrations are utilized. Furthermore, the study demonstrates that certain reported 
biologies (e.g. calcium release) for C1P are not via activation of eicosanoid biosynthesis. 
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Materials and Methods 
 
Materials: All cultured cells were obtained from American Type Culture Collection 
(ATCC). [γ-32P]ATP (3000 Ci/mmol) was purchased from Amersham Pharmacia Biotech 
(Piscataway, NJ). D-e-C18:1 ceramide-1-phosphate, D-e-C16:0 ceramide-1-phosphate, D-e-
C6:0 ceramide-1-phosphate and D-e-C2:0 ceramide-1-phosphate for the treatment of A549 
were purchased from Avanti or produced via large scale phosphorylation of ceramide. C1P 
used in the treatment of NR8383 cells, Methanol, Ethanol and dodecane are from Sigma-
Aldrich. Ceramide and PA were purchased from Avanti Polar Lipids. Dulbecco's modified 
Eagle's medium (DMEM), RPMI, fetal bovine serum (FBS) and Penicillin/Streptomycin 
(100 units/ml penicillin G sodium, and 100 µg/ml streptomycin sulfate) were obtained 
from Invitrogen Life Technologies, Carlsbad, CA. 
  
Cell culture: A549 lung adenocarcinoma cells were grown in 50% RPMI 1640 and 50% 
Dulbecco's modified Eagle's medium-DMEM supplemented with L-glutamine, 10% (v/v) 
FBS, 2% (v/v) Penicillin/Streptomycin.  Cells were maintained at less than 80% 
confluency under standard incubator conditions (humidified atmosphere, 95% air, 5% CO2, 
37 °C). RAW macrophages were grown in DMEM supplemented with L-glutamine, 10% 
(v/v) FBS, 2% (v/v) Penicillin/Streptomycin. For treatments, the medium was replaced 2 
hours prior to the addition of the agonist by DMEM containing 2 % FBS and 2 % 
Penicillin/Streptomycin. Alveolar macrophage cells (NR8383) were cultured in Ham's F12 
medium supplemented with 15% FBS, 2.74 mg/ml of glucose, 2% (v/v) 
76 
Penicillin/Streptomycin. Floating and adherent cells were collected after centrifugation, 
resuspended in fresh medium, and seeded in new culture dishes. They were then cultured 
in a humidified atmosphere containing 5%CO2 at 37°C.  
 
Dispersion of C1P in aqueous solution: C1P is dissolved in ethanol to make a 10 mM 
solution. The required amount of C1P from this stock solution is dried down under N2 gas. 
Water is added to the dried ceramide to the desired concentration. The solution is then 
sonicated on ice until a clear solution is obtained and used soon thereafter. 
 
Dispersion C1P in ethanol/dodecane:  Ethanol and dodecane is mixed at a ratio of 98:2, 
followed by vortexing and pre-warmed at 37 °C. Meanwhile, C1P is dissolved in 
chloroform:methanol 1:1. The required volume is then dried down under N2 gas.  The pre-
warmed alcohol:dodecane mixture is added to the dried C1P such that the final 
concentration is 2.5 mM (a stock solution up to 10 mM can be made). This mixture is 
thoroughly vortexed and incubated at 37°C for a further 20 minutes followed by further 
vortexing. The stock solution, thus prepared, is diluted to the required concentration using 
ethanol/dodecane and used to treat the cells.  
 
Treatment of cells with phospholipids: The stock solution of C1P in delivery medium is 
incubated at 37 °C followed by vortexing. C1P is diluted to the appropriate concentration 
in ethanol/dodecane solution, and added to cells at a dilution of 1:1000. This concentration 
is recommended to prevent adverse effects on cells by the delivery medium itself. 1-
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palmitoyl-2-oleoyl-sn-glycero-3-phosphate (PA) and ceramide similarly prepared in 
ethanol/dodecane was included as a sham control at the same concentration as the 
treatment.  
 
Mixed micelle assay for cPLA2α: cPLA2α activity was measured in a PC-mixed micelle 
assay in a standard buffer composed of 80 mM HEPES, pH 7.5, 150 mM NaCl, 10 µM free 
Ca2+, and 1 mM dithiothreitol. The assay also contained 0.3 mM 1-palmitoyl-2-
arachidonoylphosphotidylcholine (PAPC) with 250,000 dpm of [14C]PAPC, 2 mM Triton 
X-100, 26% glycerol, and 500 ng of purified cPLA2α protein in a total volume of 200 µl. 
To prepare the substrate, an appropriate volume of cold PAPC in chloroform, indicated 
phospholipids, and [14C]PAPC in toluene/ethanol 1:1 solution were evaporated under 
nitrogen. Triton X-100 was added to the dried lipid to give a 4-fold concentrated substrate 
solution (1.2 mM PAPC). The solution was probe sonicated on ice (1min on, 1 min off for 
3 min). The reaction was initiated by adding 500 ng of the enzyme and was stopped by the 
addition of 2.5 ml of Dole reagent (2-propanol, heptane, 0.5 M H2SO4; 400:100:20, v/v/v). 
The amount of [14C]AA produced was determined using the Dole procedure as previously 
described (97). All of the assays were conducted for 45 min at 37 °C. Statistical and kinetic 
analysis was performed using Sigma-Plot Enzyme Kinetics software, version 1.1, from 
SYSSTAT software, Inc.  
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Quantification of arachidonic acid release:  A549 cells (5 x 104) were labeled overnight 
with 5 µCi/ml [3H]arachidonic acid (5 nM). Cells were washed and placed in Dulbecco's 
modified Eagle's medium supplemented with 2% fetal bovine serum for 2 h. Following 
treatment, medium was transferred to 1.5-ml polypropylene tubes, centrifuged at 10,000 x 
g, and [3H]AA (and metabolites) cpm were determined by scintillation counting. Results 
were controlled for equivalent number of cells quantified by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay as described (32) and by verification of total AA 
labeling by scintillation counting. In arachidonic acid release experiments of NR 8383 
cells, both adherent and floating cells were collected and seeded in 35 mm plates at a 
density of 1 x106 cells/ml. [3H]-Arachidonic acid (0.20 µCi/ml) was added and cells 
incubated overnight. The cells were then washed twice with Ham's F12 medium 
supplemented with 0.2% BSA, and experiments were performed in Ham's F12 medium 
supplemented with 0.1% BSA. Six hours after addition of appropriate agonist, the medium 
was collected and centrifuged at 10000 x g for 5 min. The radioactivity in the supernatants 
was measured using a liquid scintillation counter Packard Tri-Carb2700TR (Meriden, CT). 
An aliquot of the supernatant was used in some experiments for analysis of radiolabeled 
compounds confirming that most of the radioactivity was in arachidonate. 
 
PGE2 assay: The ELISA plate (Cayman Chemical), coated with goat anti-mouse IgG was 
loaded at 50 μL per well of standard/sample, where the sample was diluted at 1 in 40 in 1X 
EIA buffer, 50 μL of PGE2 EIA AChE tracer (Cayman Chemical), and 50 μL of PGE2 
monoclonal antibody (Cayman Chemical). The control wells received 50 μL of 1X EIA 
79 
buffer along with 50 μL of PGE2 EIA AChE tracer and 50 μL of PGE2 monoclonal 
antibody. The plate was covered and kept at 4 oC for 16 hours. The plate was then washed 
and 200 μL of Ellman’s reagent (Cayman Chemical) was added to each well and was 
allowed to develop in the dark with low shaking at room temperature for 90 minutes. 
Following the developing step, absorbance in each well at 405 nM was read using a 
microplate spectrophotometer (BMG Labtech FLUOStar Optima). This assay was 
normalized by WST-1 assay (Roche Diagnostics) following the manufacturer’s 
instructions. WST-1 reagent (10 % of the total volume) was added to the cells and the plate 
was incubated at 37 °C for 30 minutes. The optical density was then measured (at 450 nM 
vs. a reference of 630 nM) using microplate spectrophotometer (BIO-TEK KC Junior).  
 
Confocal microscopy: A549 cells were seeded onto 22×22 mm coverslips (Fisher) in 35 
mm diameter plates in their appropriate media and incubated at 37 ˚C under 5 % CO2 
overnight. The following day, cells were transfected with adenovirus containing GFP-
cPLA2 at 10 MOI. After 48 hours incubation, the cells were treated with C1P or PA (1µM) 
solubilized in ethanol dodecane (98:2). Cells were washed twice with PBS to remove the 
excess of protein and then fixed on the coverslips with 100 % cold methanol for 10 min at 
-20 °C. Coverslips were mounted in 10 mM n-propagalate in gycerol, and were viewed 
using Olympus BX50WI confocal microscope at 488 nM (Fluoview detector) using a 40x 
liquid immersable lens with a 1.5x-enhanced magnification. microscopy. 
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Lipid uptake analysis by radiolabeled C1P: D-e-C18:1 ceramide was subjected to 
enzymatic conversion to C1P in the presence of λ32P labeled ATP as previously described 
(41, 75) and purified as previously described (41, 75). A549 cells were seeded onto 10 cm 
dishes at a density of 5 x 104 and incubated overnight under standard incubation 
conditions. On the day of treatment the cells were washed in PBS and transferred to media 
containing 2% serum and incubated under standard incubation conditions for two hours. 
Lipids were prepared by mixing radiolabeled and unlabeled C1P such that the final lipid 
concentration was 1mM. These lipids were solubilized either in EtOH/dodecane as 
described elsewhere, or by sonicating in water for five minutes. The resulting 1mM lipid 
solutions were added to the cells at a dilution of 1:1000 and incubated for two hours. At 
the end of the incubation period the cells were washed three times in ice cold PBS prior to 
fractionation.  
 
Subcellular fractionation of plasma membrane versus internal membranes: The plasma 
membranes of the harvested cells were disrupted by four consecutive freeze thaw cycles. 
The internal membranes were separated from the plasma membrane by centrifugation at 
10,000 g for 5 minutes. The two fractions were counted separately using a Beckman LS 
6500 scintillation counter.  
 
Subcellular fractionation of different organelle membrane fractions: A549 cells in 10 
cm plates treated for lipid uptake, were suspended in buffer containing 20 mM HEPES (pH 
7.4), 10 mM KCl, 2 mM MgCl2, 1 mM EDTA, 0.25 M sucrose, and protease inhibitor 
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cocktail (Sigma). The plasma membranes of the harvested cells were disrupted by four 
consecutive freeze thaw cycles followed by homogenization by passing through a 23G 
needle 10 times. Subcellular fractionation was performed by differential centrifugation 
using a modification of the technique described by Maceyka et al (98). The postnuclear 
supernatants were centrifuged at 5,000 g for 10 min to generate the heavy membrane 
(mitochondria- and trans-Golgi-enriched fraction). The supernatants were then centrifuged 
at 17,000 g for 15 min to obtain the light membrane fraction (endoplasmic reticulum- and 
cis-Golgi-enriched fraction). The remaining supernatants were centrifuged at 100,000 g for 
1 h to obtain the plasma membrane and the cytosol. 100 µl of each fraction was counted 
using a Beckman LS 6500 scintillation counter.  
 
Mass spectrometric analysis: (1 x 106) A549 cells were seeded onto 10 cm dishes and 
incubated overnight under standard incubator conditions. The following day cells were 
washed with PBS and treated with 1µM solution of D-erythro-C18:1 C1P or ceramide for 2 
hours in 2% medium. Thereafter, the cells were washed and harvested in cold PBS as 
described (99). The cell pellets were stored at -80°C until extraction and analyzed by mass 
spectrometry. An aliquot of cells was taken for standardization (Total DNA). The lipids 
were extracted as described by Merrill et al (99) and quantified using liquid 
chromatography electrospray ionization tandem mass spectrometry using a Shimadzu 
HPLC system coupled to a 4000 QTRAP mass spectrometer (Applied Biosystems) as 
described (99).  
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Statistical analysis: Statistical differences between treatment groups were determined by a 
2-tailed, unpaired Student t test when appropriate. P values less than or equal to 0.05 were 
considered significant.  
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Results  
 
C1P activates cPLA2α in a chain length-specific manner. 
 
C1Ps ranging from acyl chain lengths of 14 to 26 carbons are present in mammalian cells 
with C16:0, C18:0 and C24:1 generally being the more abundant. However, there are reports as 
to the existence of chain lengths as short as 2 carbons (100) and many studies have utilized 
C2-C1P as an exogenous agonist (37, 101, 102).  In this study the ability of various chain 
lengths of C1P to activate cPLA2α was examined. To this end, we utilized C2, C6, C16 and 
C18:1 C1P and an established in vitro assay for cPLA2α. All chain lengths of C1P except C2-
C1P substantially activated cPLA2α (Figure 3.1). C2-C1P induced an insignificant increase 
in cPLA2α activity similar to that of our previous reports of S1P, LPA and PA (Figure 3.1). 
C4-C1P was also able to activate the enzyme to the same extent as C18:1-C1P (data not 
shown). Thus, C1P requires an acyl chain length of ≥ 4 to 6 carbons for significant 
activation of cPLA2α.  
84 
 
Figure 3.1. Activation of cPLA2α by C1P is dependent on the acyl chain length. 
cPLA2α activity was measured as a function of PC molar concentration in the absence  and 
presence of 4 mol % D-erythro C2, C6, C16, and C18:1 C1P for 45 min at 37 °C as described 
under “Experimental Procedures”. The PC mole fraction was held constant at 0.137. Data 
are presented as cPLA2α activity measured as nanomoles of arachidonic acid 
produced/minute/milligram of recombinant cPLA2α± S.E.  
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Natural ceramide-1-phosphate is a lipid-specific inducer of AA release, cPLA2α 
activation and eicosanoid synthesis.  
 
The recent report by Bornancin and coworkers (96) elegantly and comprehensively 
demonstrated that the biological effects on cells, in particular PGE2 synthesis and cell 
death, were not lipid specific when: 1) high doses of lipids were used (10 μM), and 2) the 
lipids were delivered using ethanol/dodecane. In 2003, our laboratory demonstrated that a 
lipid-specific effect on the activation of cPLA2α, induction of AA release, and eicosanoid 
synthesis was observed for C1P when low doses of lipids (≤ 1 μM) were utilized using the 
ethanol/dodecane delivery system (32, 67). Furthermore, a collaboratory study with 
Spiegel and co-workers demonstrated no loss of cell viability when < 5µM of C1P was 
delivered to cells via ethanol/dodecane. Therefore, we hypothesized that the dose of lipids 
utilized when delivered via ethanol/dodecane was the reason for these contrasting 
observations, and chose to validate this lipid delivery system before proceeding to examine 
the chain length specificity of C1P activation of cPLA2α in cells. Therefore, we first 
examined the effects of related/similar lipids delivered via EtOH/dodecane (98:2 v/v) on 
cPLA2α translocation, AA release, and eicosanoid synthesis. Treatment of A549 cells with 
D-erythro-C18:1 ceramide-1-phosphate, a naturally occurring sphingolipid, rapidly induced 
an increase in AA release (Figure 3.2, Panel A) with concomitant increase in PGE2 
synthesis (Figure 3.2, Panel B). This effect was dose-dependent with an EC50 of 400 nM 
C1P at 2 hours with 200 nM C1P inducing a significant increase in AA release and PGE2 
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synthesis. Therefore, treatment of cells with C1P induces activation of a PLA2 species and 
induces a dose-dependent increase in AA release, which subsequently leads to eicosanoid 
production. As previously reported by our laboratory, C1P at ≤1µM had no effect on cell 
viability (Pettus el al 2003, Mitra et al  2007, data not shown) 
 
To demonstrate that the effect of C1P on AA and PGE2 release was lipid-specific, A549 
cells were also treated in the same experiments with various doses of the closely related 
lipid, di-oleolyl phosphatidic acid (PA), and a direct metabolite of C1P, and D-erythro 
C18:1 ceramide (Cer) (Figure 3.2A). Both ceramide and PA had only marginal effects on 
AA release (approximately 2-fold) in the sub-micromolar range as compared to treatment 
of A549 cells with the vehicle control requiring at least 750 nM for the effect.  PGE2 
synthesis followed a similar patter of induction (Figure 3.2B). Higher doses of PA (≥1µM) 
did induce dramatic AA release (62% as effective as C1P on AA release) in accord with 
the findings of Bornancin and co-workers (96) (data not shown). Thus, C1P is a potent and 
specific effector of AA and PGE2 release in cells when sub-micromolar doses of lipids 
were added exogenously in ethanol/dodecane.  
 
We then examined the lipid specificity of cPLA2α activation. Upon activation, cPLA2α is 
translocated from the cytosol to associate with the Golgi and perinuclear membranes in 
cells (32). Therefore, to determine the lipid specificity of cPLA2α activation/translocation 
in cells, we examined whether C1P versus PA affects the association of cPLA2α with 
cellular membranes using  cPLA2α fused to green fluorescent protein (GFP). Treatment of 
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A549 cells with 500 nM C1P for 2 hours induced a significant increase of cPLA2α in the 
Golgi and perinuclear membranes (Figure 3.2C). The same doses of PA or the delivery 
medium alone had no effect on the translocation of cPLA2α (Figure 3.2C).   
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Figure 3.2: The effects of natural ceramide-1-phosphate on AA release and PGE2 
synthesis. Panel A. The effects of ceramide-1-phosphate on AA release is lipid specific 
at low doses. A549 cells (5 x 104) were labeled overnight with 5 μCi/mL [3H]-arachidonic 
acid (5 nM). Cells were washed and placed in DMEM supplemented with 2% fetal bovine 
serum for two hours, followed by treatment with 0.1, 0.2, 0.3, 0.4, 0.5, 0.75 and 1 μM of 
D-e-C18:1 C1P (●), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (PA) (▼) or D-e-C18:1 
ceramide (○) solubilized in 2% dodecane/98% EtOH (final concentration in treatments was 
0.002% dodecane/0.098% EtOH) for 2 hours. For quantification of AA release, media was 
transferred to 1.5 mL polypropylene tubes, centrifuged 10,000 x g, and 3H arachidonic acid 
determined by scintillation counting. The results are presented as DPM of 3H-arachidonic 
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acid per mL of media controlled for equivalent number of cells by MTT assay. Data are 
representative of 15 separate determinations on 5 separate occasions.  
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Figure 3.2. Panel B. Natural ceramide-1-phosphate, but not the structurally similar 
PA nor ceramide is capable of inducing PGE2 synthesis. A549 cells (5 x 104) were 
washed and placed in DMEM supplemented with 2% fetal bovine serum for two hours. 
Cells were then treated with 0.1, 0.2, 0.4, 0.5, 0.75 and 1 μM D-e-C18:1 C1P (●), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphate (PA) (○) or D-e-C18:1 ceramide (▼), solubilized 
in 2% dodecane/98% EtOH (final concentration in treatments was 0.002% 
dodecane/0.098% EtOH) for 2 hours. For measurement of PGE2 levels, media were 
assayed according to manufacturer's instructions using the Prostaglandin E2 monoclonal 
EIA Kit from Cayman Chemical (Ann Arbor, MI, Catalog No. 514010). Briefly, media 
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containing PGE2 competes with PGE2 acetylcholinestaerase conjugate for a limited amount 
of PGE2 monoclonal antibody.  The antibody-PGE2 conjugate binds to a goat-anti-mouse 
antibody previously attached to the wells.  The plate is washed to remove any unbound 
reagents and then the substrate to acetylcholinesterase is provided.  The concentration of 
PGE2 in a sample is inversely proportional to the yellow color produced. The results are 
presented as pg of PGE2 per mL of media controlled for equivalent number of cells by 
MTT assay. Data are representative of 6 separate determinations on 2 separate occasions.  
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Figure 3.2 Panel C: cPLA2α translocates specifically in response to ceramide-1-
phosphate. A549 cells (1 x 105) were infected at 10 MOI with an adenoviral construct 
containing cPLA2α-GFP. 48 hours post infection, cells were treated with 500 nM D-e-C18:1 
Ceramide (A), 500 nM 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (PA) (B) and 500 nM 
D-e-C18:1ceramide-1-phosphate (C), all solubilized in 2% dodecane/98% EtOH (final 
concentration in treatments was 0.002% dodecane/0.098% EtOH) for 2 hours. cPLA2α 
localization was visualized using an Olympus BX50WI confocal microscope at 488 nM 
(Fluoview detector) using a 40x liquid immersable lens with a 1.5x-enhanced 
magnification. Data are representative of three separate determinations on 2 separate 
occasions. 
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To determine whether the activation of cPLA2α by C1P was dependent on delivery of C1P 
by ethanol/dodecane, naturally occurring C1P was directly sonicated in water and 
delivered to NR8383 macrophages. A significant increase in AA release at 15 µM C1P was 
observed (Figure 3.3). In addition, the stimulation of AA release in the macrophages was 
specific for C1P as other related phospholipids S1P (data not shown) and PA had no effect 
(Figure 3.3). Although higher doses are required, C1P induces activation of the eicosanoid 
cascade irrespective of delivery vehicle and in a lipid-specific manner. 
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Figure 3.3. Activation of cPLA2α by C1P is independent of its delivery medium. [3H]-
Arachidonic acid (0.20 µCi/ml) labeled NR8383 cells (1x106 cells/ml) were treated with 
C1P (●), PA (○) and H2O (▼) sonicated in water at 5, 15 and 30 µM for six hours. For 
quantification the media was collected and centrifuged at 10000 x g for 5 minutes and the 
amount of [3H] labeled arachidonic acid in the media was quantified by scintillation 
counting. The results are presented as DPM of radioactivity per mL of media.  
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Exogenous C1P is slowly metabolized to ceramide. 
 
Bornancin and coworkers (96) reported that C1P delivered by EtOH/dodecane was rapidly 
metabolized, and its uptake was not enhanced by this delivery system. We hypothesized 
that this observation on uptake and metabolism by may be due to the toxicity induced by 
using 10 µM C1P delivered with EtOH/dodecane, or the use of the unnatural analogue, 
NBD-C1P. To determine, the kinetics of C1P metabolism and also examine cellular 
uptake, A549 cells were treated with natural (D-e-C18:1) ceramide, and C1P, and the levels 
of these lipids were analyzed by mass spectrometry (Figure 3.4). C1P exogenously 
delivered by ethanol-dodecane demonstrated a rapid increase (within two hours) in the 
18:1 acyl chain length of endogenous C1P in A549 cells (Figures 3.4). The data also 
demonstrate that C1P was slowly metabolized to ceramide in A549 cells (Figure 3.4 inset) 
with only a small increase in C18:1 ceramide upon addition of D-e-C18:1 C1P to cells. This 
translated into only a 2.8 % increase in total ceramide in accord with the recent 
collaboratory publication with Spiegel and co-workers (103). Thus, natural C1P delivered 
in low doses to A549 cells is not metabolized rapidly to ceramide at sub-micromolar 
concentrations. 
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Figure 3.4: C1P is efficiently delivered to cells via EtOH/dodecane and is slowly 
metabolized to ceramide. A549 cells (1 x 106) were treated with 500µM D-e-C18:1 C1P 
for 2 hours.  The cells were then harvested and lipids extracted followed by analysis by 
mass spectroscopy. Data are presented as pmols of lipid. Panel A inset. Exogenously 
added C1P is slowly metabolized to ceramide.  A549 cells (1 x 106) were treated with 
500µM D-e-C18:1 C1P for 2 hours.  The cells were then harvested and lipids extracted 
followed by analysis by mass spectroscopy for C1P and ceramide (inset). Data is presented 
as pmols lipids.  
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C1P is delivered more efficiently to internal membranes with EtOH/dodecane. 
  
Currently the delivery of C1P as vesicles is considered non-toxic to cells. However, the 
relative efficiency of this method for delivering C1P to internal membranes when 
compared to EtOH/dodecane system is not known. To investigate the uptake efficiency of 
C1P, we utilized 32P-labeled C1P at low doses to examine the uptake of C1P delivered via 
ethanol/dodecane versus vesicle-based delivery (Figure 3.5). Following treatment (500 nM 
C1P for 2 hours), the concentration of radiolabeled C1P in the total internal membranes 
was found to be increased >2 fold when delivered via EtOH/dodecane versus vesicles 
(Figure 3.5A). Thus, C1P delivered via the EtOH/dodecane method is more efficient in 
delivering C1P to internal membranes.  
 
In order to further compare the intracellular membranes for lipid delivery by 
ethanol/dodecane versus vesicles, radiolabeled C1P (32P) was delivered using both 
ethanol/dodecane and sonicated vesicles followed by subcellular fractionation as 
previously described by our laboratory. The ethanol/dodecane delivery system was more 
efficient at delivering C1P to all internal membranes including the nucleus, mitochondria, 
trans-Golgi, the ER, and the Cis-Golgi when compared to vesicular delivery system 
(Figure 3.5B). Importantly, C1P was delivered > 3 fold by ethanol/dodecane to the site of 
cPLA2α translocation (trans-Golgi enriched fraction) compared to sonicated vesicles. 
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Western analysis was used to confirm appropriate fractionation as previously described 
(Figure 3.5C) (104). 
 
 
 
Figure 3.5: C1P is efficiently taken up by cells into internal membranes when 
delivered via ethanol/dodecane. Panel A. A549 cells (1 x 106) were treated for 2 hours 
with radiolabeled, 500µM D-e-C18:1 C1P solubilized in either ethanol/dodecane or by 
sonication.  The cells were then harvested and lysed by freeze thawing. The plasma 
membranes were separated from the internal membranes and the amounts of radiolabeled 
lipids in the different fractions measured by scintillation counting. The results are 
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presented as the fold increase of the levels of C1P over background in each fraction for the 
different methods of delivery.  
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Figure 3.5 Panel B: C1P delivered via ethanol/dodecane system reaches specific 
internal membranes with higher efficiency. A549 cells (1 x 106) were treated for 2 hours 
with radiolabeled, 500µM D-e-C18:1 C1P solubilized in either ethanol/dodecane or by 
sonication.  The cells were then harvested and lysed by freeze thawing and homogenized. 
The resultant mixture was subjected subcellular fractionation via differential centrifugation 
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as previously described (104). All fractions were confirmed as previously described by our 
laboratory (104). The results are presented as a comparison of the levels of C1P in each 
fraction for the different methods of delivery of C1P. 
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Figure 3.5 Panel C: Differential centrifugation allows the separation of the different 
organelles into different subcellular fractions. A549 cells treated and subjected to 
subcellular fractionation as in 5B to obtain nuclear (N), mitochondrial and trans-Golgi 
(M,TGN), Endoplasmic Reticulum (ER), plasma membrane (PM) and cytosolic (Cyt) 
fractions. All fractions were probed with organelle specific markers to assay for purity of 
the fractions. Anti-lamin AC (santa Cruz 1:1000) for nuclear, anti-mitochondrial (AbCam 
1:1000), anti-TGN46 for trans-Golgi (AbCam 1:1000), anti- protein disulfide isomerase 
(PDI) for ER(AbCam 1:1000), anti-caveolin 1 for plasma membrane (Santa Cruz 1:1000). 
Note: Only the ER fraction demonstrated the proper PDI signal. The chemiluminescence 
signals observed in the other fractions are non-specific. 
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Long chain C1P specifically induces AA release by cPLA2α 
 
Once the ethanol/dodecane delivery system was established to deliver C1P to the proper 
organelles and produce a lipid specific activation of cPLA2α, we investigated the effects of 
C2, C6, C16 and C18:1 C1P treatment on cells. Although, the cellular concentration of C2-
C1P in internal membranes increased to the same extent as the C18:1-C1P when delivered 
by the ethanol/dodecane delivery system (Figure 3.6A inset), induction of AA release was 
not observed (Figure 3.6A). Thus, intracellular activation of a PLA2 species by C1P is also 
chain length specific.  
 
To investigate, whether C2-C1P could activate cPLA2α in cells, we again delivered short 
chain (C2) and long chain (C18:1) C1P to A549 cells using the ethanol/dodecane system. 
The levels of membrane associated and cytosolic cPLA2α following C1P treatment was 
measured. Western blot analysis revealed a significant increase of cPLA2α in the 
membrane fraction of the C18:1 treated cells. However, no increase in cPLA2α in the 
membrane fraction was observed in C2-C1P treated cells (Figure 3.6B). 
 
Recently our laboratory has identified the C1P binding site on cPLA2α which allowed us to 
generate a mutant cPLA2α (R57A/K58A/R59A) that significantly reduced binding to C1P 
yet has no effects on structure, basal activity or the calcium response (105). Using GFP-
tagged wild type and mutant cPLA2α, we investigated their translocation in response to 
C18:1-C1P delivered by ethanol/dodecane in A549 cells.  Confocal analysis revealed > 3-fold 
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translocation of the wild type cPLA2α compared to the mutant in response to C18:1-C1P 
(Figure 3.6C). As all other functionalities of the mutant cPLA2α are the same as the wild 
type, we conclude that activation of cPLA2α by C1P is via a direct interaction and  not 
through an indirect effect of other nonspecific biologies associated with the lipid. 
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Figure 3.6. Naturally occurring C1P are the best activators of cPLA2α in-vivo. Panel 
A. A549 cells (5 x 104) were labeled overnight with 5 μCi/mL [3H]-arachidonic acid (5 
nM). Cells were washed and placed in DMEM supplemented with 2% fetal bovine serum 
for two hours. Cells were then treated with either ethanol/dodecane alone, media (No C1P) 
or 0.5 μM D-erythro C2, C6, C16 and C18:1 C1P solubilized in 2% dodecane/98% EtOH 
(final concentration in treatments was 0.002% dodecane/0.098% EtOH) as previously 
described for C1P(32) for 2 hours. For quantification of AA release, media was transferred 
to 1.5 mL polypropylene tubes, centrifuged 10,000xg, and 3H cpm determined by 
scintillation counting. Results were controlled for equivalent number of cells quantified by 
WST assay. The results are presented as fold increase in AA release when compared to 
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ethanol/dodecane treatment. The results are an average of 3 experiments ± SD. Panel A 
inset. Ethanol/dodacane system successfully delivers both the long and short chain C1P’s 
to cells. A549 cells (1 x 106) were treated for 2 hours with 1µM D-e-C2 C1P or D-e-
C18:1C1P. The cells were then harvested and analyzed by mass spectrometry as previously 
described. Data are expressed as increase in pmol quantity of the lipid over that of the 
controls. 
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Figure 3.6. Panel B. cPLA2α translocates to the membrane in response to natural long 
chain C1P but not the short C2-C1P. A549 cells (1 x 105) were infected at 10 MOI with 
an adenoviral construct containing cPLA2α-GFP. 48 hours post infection, cells were 
treated with 500 nM D-e-C18:1 C1P or C2-C1P solubilized in 2% dodecane/98% EtOH 
(final concentration in treatments was 0.002% dodecane/0.098% EtOH) for 2 hours. The 
cells were subsequently lysed and centrifuged at 100,000 x g to separate membranes from 
the cytosol. Equal total protein from each fraction was subjected to western analysis and 
probed for the indicated proteins. Data are representative of three separate determinations 
on 2 separate occasions.  
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Figure 3.6. Panel C. Translocation of cPLA2α in response to C1P is due to a direct 
interaction with C1P. A549 cells (1 x 105) were infected at 10 MOI with an adenoviral 
constructs containing wild type and mutant (R57A/K58A/R59A) cPLA2α-GFP. 48 hours 
post infection, cells were treated with 1µM D-e-C18:1 C1P solubilized in 2% dodecane/98% 
EtOH (final concentration in treatments was 0.002% dodecane/0.098% EtOH) for 3 hours. 
cPLA2α localization was visualized using an Olympus BX50WI confocal microscope at 
488 nM (Fluoview detector) using a 40x liquid immersable lens with a 1.5x-enhanced 
magnification. Data are representative of three separate determinations on 2 separate 
occasions. 
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To further demonstrate that activation of cPLA2α is limited to naturally occurring C1P, we 
compared the ability of the dimethyl ester of D-e-C18:1 C1P and the naturally occurring D-
e-C18:1 C1P (Figure 3.7A) to activate cPLA2α in vitro and in cells. Compared to the natural 
counterpart, dimethyl C1P was not able to activate of cPLA2α in vitro (Figure 3.7B) and 
was a very poor inducer of AA release from cells (Figure 3.7C). 
 
 
 
 
Figure 3.7 Panel A: D-e-C18:1 dimethyl ester of C1P is structurally similar to D-e-C18:1 
C1P. a) D-e-C18:1 C1P, b) D-e-C18:1 dimethyl C1P. 
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Figure 3.7 Panel B: The structurally similar dimethyl ester of D-e-C18: C1P does not 
activate cPLA2α in vitro. cPLA2α activity was measured as a function of PC molar 
concentration in the presence of 4 mol % D-e-C18:1 C1P and dimethyl D-e-C18:1 C1P for 45 
min at 37 °C as described under “Experimental Procedures”. The PC mole fraction was 
held constant at 0.137. Data are presented as cPLA2α activity measured as nanomoles of 
arachidonic acid produced/minute/milligram of recombinant cPLA2α± S.E.  
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Figure 3.7 Panel C: Compared to naturally occurring C1P, the dimethyl ester of D-e-
C18: C1P is a very poor inducer of arachidonic acid release. A549 cells (5 x 104) were 
labeled overnight with 5 μCi/mL [3H]-arachidonic acid (5 nM). Cells were washed and 
placed in DMEM supplemented with 2% fetal bovine serum for two hours. Cells were then 
treated with either ethanol/dodecane alone, media (No C1P) or 0.5 μM dimethyl ester of 
D-e-C18:1 C1P or the naturally occurring D-e-C18:1 C1P solubilized in 2% dodecane/98% 
EtOH for 2 hours (the final concentration in treatment groups was 0.002% 
dodecane/0.098% EtOH as previously described for C1P (32)). For quantification of AA 
release, media was transferred to 1.5 mL polypropylene tubes, centrifuged 10,000 x g, and 
3H cpm determined by scintillation counting. Results were controlled for equivalent 
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number of cells quantified by WST assay. The results are presented as fold increase in AA 
release when compared to ethanol/dodecane treatment. The results are an average of 3 
experiments ± SD.  
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DISCUSSION  
 
Previously, our laboratory reported in 2003 that C1P delivered in ethanol:dodecane 
stimulated cPLA2α in A549 cells in a lipid-specific manner (32). However, the acyl chain 
length specificity of C1P for this interaction was not examined. In both in-vitro and 
cellular studies, C2-C1P was not able to significantly increase AA release over control. 
Therefore, this study demonstrates that an acyl chain length of  > 2 carbons was necessary 
for activation of cPLA2α. Furthermore, data from cellular studies, where C1P was 
delivered in ethanol/dodecane, indicate that the naturally occurring C1P’s are the most 
potent activators of cPLA2α with C16 and C18:1 C1P giving over a 4-fold increase in AA 
release over C2-C1P.  
 
These findings have relevance to the reported biological mechanisms attributed to 
exogenous C1P treatment. For example, several studies, using C2 C1P have shown 
intracellular increases in Ca+2 (102, 106). As cPLA2α is a calcium-stimulated enzyme, it 
may be argued that the activation of cPLA2α by C1P is due to an increase in intracellular 
calcium. The current data clearly demonstrate that C2 C1P does not cause activation of 
cPLA2α in vitro, nor release arachidonic acid through the activation of cPLA2α when 
delivered to cells. Thus the activation of cPLA2α by C1P is not via an increases in the 
intracellular Ca+2 levels, corroborating our earlier findings that ceramide kinase is required 
for activation of cPLA2α by calcium ionophores. Furthermore, induction of calcium release 
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observed in response to C2-C1P is not via the reverse mechanism of activation of cPLA2α 
and subsequent generation of PGE2 a known inducer of Ca+2 release. 
 
Thus, the current study also highlights the usefulness of C2-C1P in studying the biological 
effects of C1P that are independent of the activation of cPLA2α. For example, the 
stimulation of DNA synthesis and cell division observed by exogenous treatment with C2 
C1P (37) is not due to any downstream effects of the activation of cPLA2α and increases in 
eicosanoids. Therefore, C2-C1P is now a “tool” to examine non eicosanoids biologies 
regulated by C1P. Furthermore, C2-C1P may also be used to differentiate between direct 
targets of cPLA2α and A-Smase. 
 
This study also provides additional proof that translocation of cPLA2α to membranes in 
response to C1P is via a direct interaction as C1P binding site mutants showed 
significantly reduced translocation (Figure 3.6C). This mutant can now be used as a tool to 
investigate C1P independent translocation of cPLA2α. As the mechanisms and triggers 
behind the generation of C1P is not currently understood, this is an important tool to 
differentiate between agonists causing C1P-independent translocation from those causing 
translocation via a direct increase in C1P.  
 
The observation that cPLA2α is activated by long chain naturally occurring C1P is in 
agreement with our previous work (41) with regards to ceramide kinase, the only known 
mammalian enzyme to date to produce C1P. Substrate preference of CERK is for 
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ceramides containing acyl chains of at least 12 carbons (41). Confocal studies demonstrate 
that in A549 cells CERK localizes to the Golgi apparatus, the site of AA release by cPLA2α. 
Thus, it is quite clear that ceramide phosphorylation by CERK is geared towards producing 
C1P causing maximal activation of cPLA2α. 
 
 This study also addresses the recent publication by Bornancin and co-workers, which 
raised doubts as to the lipid specificity of the activation of cPLA2α by C1P when delivered 
via the well established ethanol/dodecane system (96). We specifically show that the 
stimulation of arachidonic acid release in the macrophages and A549 cells were specific 
for C1P as other related phospholipids such as ceramide and PA failed to do so. The lipid-
specific effect required the use of low doses of C1P (≤ 1 μM) as previously reported by our 
laboratory. C1P at concentrations ≤ 500 nM demonstrated complete lipid specificity in the 
induction of AA release from A549 cells. In accord with the recent report by Bornancin 
and co-workers (96), lipid specificity was lost as concentrations of phospholipids increased 
above 1 μM. The loss of lipid specificity correlated with the loss of cell viability as 
recently reported by Spiegel and co-workers (103) and Bornancin and co-workers (96). 
Thus, our study demonstrates that the contrasting findings between the two laboratories 
was the difference in concentration of C1P utilized. C1P is indeed a specific activator of 
AA release and cPLA2α activation when low concentrations are utilized and no loss of cell 
viability is observed. 
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In agreement with the lipid-specific effect of C1P on AA release, the presented data also 
shows that C1P dispersed in water interacts readily with NR8383 macrophages to induce 
arachidonic acid release. This was also found in A549 cells, but higher concentrations were 
required than with the use of the EtOH/dodecane system (data not shown). The observation 
that C1P can activate cPLA2α in the absence of dodecane, or any other organic solvent, is 
also relevant because it discards any possible non-specific interaction of the phospholipid 
with the organic compounds used for its delivery to cells in culture. In this regard, it should 
be emphasized that the stimulatory effect of C1P on proliferation of rat-1 fibroblasts and 
the inhibition of apoptosis in bone marrow-derived macrophages were all observed using 
C1P dispersed in water, in the absence of any organic solvent (37, 39, 91). Therefore, 
ideally, lipids should be delivered in aqueous solutions so as to avoid any side effects that 
might be generated when organic solvents are added to biological tissues or cells in 
culture. Unfortunately, high concentrations of the phospholipids are required and in the 
case of some cell types (e.g. A549 cells), vesiculated phospholipids are not as efficiently 
transported to certain internal membranes (e.g. trans-Golgi). In these cases, the 
dodecane/alcohol delivery system is an alternative for the enhancement of lipid uptake. 
 
In conclusion, the presented study answers the contrasting observations from several 
laboratories on the biological effects of lipids delivered by ethanol/dodecane. This study 
also demonstrates that the alcohol/dodecane delivery system can be utilized to examine 
biological effects by specific lipids as long as certain controls are observed. In particular, 
researchers need to utilize low doses of lipids, less than 1 μM. Doses higher than 1 μM 
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have effects on cell stress and viability, which can cause misinterpretation of results. The 
metabolism of the lipid is also of key importance as well as uptake, thus the utilization of 
closely-related lipids as well as direct metabolites of similar solubilities should be utilized 
as specificity controls. Importantly, all of these parameters need to be established for each 
specific cell type as viability may be affected at lower concentrations. Furthermore, 
monitoring of efficient uptake of the lipid should also be undertaken. With these measures 
observed, this study demonstrates that the dodecane delivery system for lipids can be 
utilized to study specific biological effects especially when coupled to genetic, cell 
biology, and enzymology approaches. Lastly, this study also demonstrates that the C1P-
cPLA2α interaction is structurally specific with proper acyl chain length being an essential 
criterion for activation of the enzyme. Furthermore, cellular biologies observed from 
treatment of cells with C2-C1P cannot be attributed to cPLA2α activation and subsequent 
eicosanoids synthesis. 
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CHAPTER 4:  A VALIDATED METHOD FOR THE QUALITATIVE AND 
QUANTITATIVE ANALYSIS OF C1P 
 
INTRODUCTION 
 
It has been well over a decade since the first biological activity of Ceramide 1 phosphate 
was described by Gomez-Munoz. Since then the number of biological activities attributed 
to C1P has been steadily increasing further enhancing its recognition as an important lipid 
signaling molecule. Currently C1P  has been demonstrated to play a role in DNA 
synthesis, activation of cPLA2α leading to the production of inflammatory mediators, 
degranulation of mast cells, inhibition of apoptosis via inhibition of aSMase. 
 
Our laboratory was the first to demonstrate that CERK and C1P have distinct roles in 
eicosanoid synthesis. We showed that treatment of several cell types with nanomolar 
concentrations of C1P induced arachidonic acid (AA) release and the synthesis of 
eicosanoids (9). Furthermore, studies using pulse labeling demonstrated that the increase in 
C1P is concurrent with the release of AA and eicosanoids in response to inflammatory 
agonists (16). Small interfering RNA (siRNA) technology to downregulate CERK blocked 
cytosolic phospholipase A2α (cPLA2α) activation, AA release, and eicosanoid production 
in response to inflammatory cytokines, ATP, and the calcium ionophore A23187 (9). 
Lastly, our laboratory defined the first intracellular target of C1P, cPLA2α, demonstrating 
that C1P interacted directly with the enzyme and functioned to increase the association of 
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cPLA2α with membranes (16). These data demonstrated a new role for CERK and its 
product, C1P, as major regulators of eicosanoid synthesis via the direct activation of 
cPLA2α (16). 
 
Until very recently an easy, accurate and reliable method for detecting cellular levels of 
C1P was unavailable. The method used by most involved either the steady state or pulse 
labeling of C1P be feeding cells with 32P labeled ATP, followed by a bligh and dyer lipid 
extreaction with base hydrolysis. These samples were then separated by TLC with the 
appropriate standards. The TLC spots corresponding to C1P as indicated by the standards 
were analyzed either by densitometry of the relevant spot in an X-ray film or by scraping 
off the spot from the plate and counting the radioactivity by scintillation counting. These 
methods have several shortfalls. First, working with of 32P is hazardous to the health. The 
use of extra protective equipment to minimize radiation exposure makes the experiments 
difficult to perform. Due to the large amount of radiation used in the labeling, in order to 
minimize effects on health the number of experiments that can be performed is limited. 
 
The development of biological Mass Spectrometry gave rise to a new tool for investigating 
the lipidome. The new soft ionization methods allowed for the identification and 
quantitation of intact biological molecules based on their molecular mass. An added layer 
of molecule specific quantitation was achieved with the use of tandem mass spectrometry 
where a biomolecule of a particular m/z can be further fragmented to identify a molecule/ 
molecular class specific fragment. However isobaric molecular species that produce 
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identical or nearly identical product ions are common in biological samples. A classic 
example of this are the prostaglandins. PGE2 and PGD2 are indistinguishable using 
standard ms2 mass spectrometry. The same is true for PGD1 and PGE1. However coupling 
mass spectrometry with a liquid chromatographic separation allows for such isobaric 
species to be separated providing an added layer of identification based on the retention 
time of the compound. 
 
The key to analysis of any biological molecule by mass spectrometry is the ability to 
efficiently ionize the molecule of interest into the gas phase. This is not a problem in the 
case of volatile compounds. However for large molecules that are not volatile, special 
techniques need to be used to produce gas phase ions. One such method is the chemical 
derivatization of the compound of interest. This method in addition to being time 
consuming is also prone to errors that lead to inconsistent quantitations. 
 
 Several direct ionization methods are now available to study biological molecules by mass 
spectrometry. Of these the most applicable are the soft ionization methods which include 
matrix assisted laser desorption ionization (MALDI) and electrospray ionization (ESI).  
However, the most successful would be a method that allows for a chromatographic pre-
separation prior to mass spectrometric analysis. This is best provided by the ESI technique 
and as such, this has become the most widely used ionization method used in the analysis 
of biomolecules by mass spectroscopy in conjunction with liquid chromatography. 
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ESI allows for continuous flow operation of HPLC-MS/MS system where compounds 
separated by the HPLC is directly fed into the ESI source for ionization and detection by 
the mass spectrometer. It is tolerant of a wide range of solvent types providing leeway in 
the development of chromatographic separation techniques. In addition ESI can accept a 
wide range of solvent flow rates and being a soft ionization method gives rise to intact 
ions. An added bonus is the ability to produce multiply charged ions which greatly extends 
the range of molecular weights that can be analyzed. 
 
Merrill et al has published a protocol for the quantitiative analysis of long chain bases (i.e. 
sphingosines, sphinganines, sphingosine-1-phosphate and sphinganine-1-phosphates) and 
C1P in the same run using reverse phase HPLC with a C18 column and a set of internal 
standards consisting of compounds in the same class as the analytes but having negligible 
biological abundance (99). While the method is well suited for analyzing long chain bases 
(LCB’s), it has two major drawbacks when used to analyze C1P which raise doubts as to 
the accuracy of data generated using mass spectroscopy. First, the reverse phase HPLC 
method show high carryovers between samples. Second, the levels of C1P reported were 
massively overestimated and not in agreement with quantification by steady state labeling. 
Thus we sought to modify this published method to allow us to accurately quantify C1P 
levels in cells that are in agreement with the amounts of C1P observed by traditional 
methods (i.e. steady state labeling studies). 
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In the course of this study it was found out that the protocol published by Merrill et all 
(99), resulted in carryovers in excess of 10% for C16:0 C1P. In addition we discovered that 
the cause for overestimated amounts of C1P is the hydrolysis of SM due to the dry down of 
samples following base treatment without proper neutralization. This led us to re-evaluate 
the published protocol and to develop a more reproducible assay for quantification of C1P 
by LC MS/MS. We show here method for C1P that is both qualitative and quantitative. In 
addition the method has been validated using steady state labeling techniques. 
 
EXPERIMENTAL PROCEDURES 
 
Cell culture: All cultured cells were obtained from the American Type Culture Collection. 
A549 lung adenocarcinoma cells were grown in 50% DMEM (BioWhittaker) and 50% 
RPMI (BioWhittaker) supplemented with 10% fetal bovine serum (Invitrogen) and 2% 
penicillin/streptomycin (BioWhittaker). Cells were maintained under 5% CO2 at 37jC by 
routine passage every 3 days. For treatments, the medium was replaced 2 h before the 
addition of the agonist by DMEM containing 2% fetal bovine serum and 2% 
penicillin/streptomycin. 
 
RNA interference: Sequence-specific silencing of CERK and CERT was performed using 
sequence-specific siRNA purchased from Dharmacon as described previously (18). The 
human CERK RNA interference sequence starts at 142 nucleotides from the start codon 
(UGCCUGCUCUGUGCCUGUAdTdT and UACAGGCACAGAGCAGGCAdTdT) (9). 
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The siRNA for human CERT was from Dharmacon (catalog No. M-012101-00). The 
sequence targets accession numbers NM_005713 and NM_031361. They were transfected 
into A549 cells using Dharmafect (Dharmacon) according to the manufacturer’s 
instructions. After incubation for 24, 48, or 72 h, cells were analyzed by Western blotting 
using a specific antibody against CERK or CERT. After incubation for 48 h, cells were 
analyzed for C1P levels by TLC or mass spectrometry. 
 
Treatment with CERT inhibitors: A549 cells were plated on 10 cm plates in the 
appropriate medium and grown at 37jC under 5% CO2 overnight such that the cells were 
80% confluent on the next day. The following morning, the media was changed to 2% 
serum and the cells were incubated for 3hrs. Stock solutions of HPA-12 inhibitor and its 
inactive racemic mixturea were made at 2mM in DMSO and were added to cells at 
dilutions of 1:1000 and 1:5000 to obtain final concentrations of 2µM and 0.4µM. DMSO 
by itself at the same dilutions were uses as the controls. 
 
Mass spectrometric analysis: A549 cells were plated on 10 cm plates in the appropriate 
medium and grown at 370C under 5% CO2 overnight. The next day, cells were subjected 
to the relevant treatment. After treatment, the plates were placed on ice and the cells were 
washed once with ice cold PBS and harvested by scraping in 200 µl of PBS. An aliquot of 
cells was taken for standardization (total protein). Lipids were extracted from the 
remaining cells as described by Merrill et al with slight modifications.  In summary, to the 
remaining cells 1 ml of methanol was added and sonicated to obtain a homogeneous mix 
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followed by the addion of 500 µl of chloroform and 500 pmols of internal standards 
(Avanti). Internal standards used were d18:1/12:0 ceramide-1-phosphate sphingomyelin, 
ceramide, glucosylceramide, lactosylceramide and d17:1-sphingosine, sphinganine, 
sphingosine-1-phosphate, sphinganine-1-phosphate. The mixture was sonicated once again 
and incubated overnight at 480C. Following day the extracts was subjected to base 
hydrolysis for 2 hrs at 37 0C and neutralized. The neutralization was confirmed with pH 
paper. Half of the extract was transferred to another tube, dried down and resuspended in 
LCB running buffer C1P together with the long chain bases were quantified using the 
modified protocol from Merrill et al (99). To the remainder of the extract 1ml of 
chloroform and 2ml of water were added, and the lower phase was transferred to another 
tube, dried down and brought up in SL running buffer and used in the analysis of 
ceramides, monohexosyl ceramides and sphingomyelins and described by Merrill et al 
(99). The lipids were separated using a Discovery C18 column on a Shimadzu HPLC and 
subjected to mass spectrometric analysis using a 4000 Q-Trap (Applied Biosystems). 
Multiple reaction monitoring (MRM) transiton monitored were 562.4/264.4 (d18:1/12:0), 
590.4/264.4 (d18:1/14:0), 618.4/264.4 (d18:1/16:0), 620.4/264.4 (d18:0/16:0), 644.4/264.4 
(d18:1/18:1), 646.4/264.4 (d18:1/18:0), 674.4/264.4 (d18:1/20:0), 702.4/264.4 (d18:1/22:0), 
728.4/264.4 (d18:1/24:1), 730.4/264.4 (d18:1/24:0), 756.4/264.4 (d18:1/26:1), 758.4/264.4 (d18:1/26:0) 
were used at collision energies +41, +43.5, +43.5, +46.0, +46.0, +48.5, +51.0, +53.5, 
+56.0, +56.0, +58.5, +58.5 V respectively. The chromatography column for C1P was a 5 
cm3 2.1mmDiscovery C18 5mmHPLC column. The mobile phase solvent A for LCB and 
C1P was 58:41:1 CH3OH/water/HCOOH and solvent B was 99:1 CH3OH/HCOOH. Both 
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contained 5 mM ammonium formate (26). The mobile phase foe solvent A for 
sphingolipids are A: CH3CN: H2O:CH3COOH 97:2:1, and solvent B: CH3OH : H2O : 
CH3(CH2)2CH2OH : CH3COOH 64:15:20:1. Both caontained 5mM ammonium acetate. 
 
RESULTS 
 
Product ion spectra of C1P in positive ion mode gives rise to more structure specific 
fragments than that from the negative ion mode. 
 
The product ion spectra of D-e-C16:0 C1P was investigated in the positive and negative ion 
modes. The ionization of C1P is better in the positive ion mode in the tested pH range (pH 
4-8) indicating that C1P act more like a base in the gas phase than an acid. Fragmentation 
of the precursor ion (m/z = 618.4) in the positive mode gave rise to the multiple structure 
indicative fragments of which the fragment for the sphingoid back bone was the most 
intense (m/z = 264.4) (Figure 4.1). Product ions obtained from fragmentation of the 
precursor ion in the negative ion mode was much less informative as to the structure of the 
species (Figure 4.2). The most prominent product ion in the negative ion mode is the PO3-  
fragment (m/z = 78.9). Neutral loss scan for the acyl chain (354.00) in the positive ion 
mode confirmed 618.4 (i.e. C16 C1P) as the only precursor ion only species in the mixture 
to contain a 16 carbon acyl chain (Figure 4.3).  
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Figure 4.1. Product ion scan of D-e-C16 C1P in the positive ion mode. D-e-C16 C1P was 
infused at a rate of 10 µl/min and the product ion scans for 20 scans collected in the 
positive ion mode at a collision energy of 40 with a collision energy spread of 10. 
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Figure 4.2. Product ion scan of D-e-C16 C1P in the negative ion mode. D-e-C16 C1P 
was infused at a rate of 10 µl/min and the product ion scans for 20 scans collected in the 
negative ion mode at a collision energy of 60 with a collision energy spread of 10. 
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Figure 4.3. Neutral loss scan of D-e-C16 C1P in the positive ion mode for the loss of 
the acyl chain. D-e-C16 C1P was infused at a rate of 10 µl/min and the product ion scans 
for 20 scans collected in the negative ion mode at a collision energy of 40 with a collision 
energy spread of 10. 
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Column heating eliminates carryover of C1P between samples. 
 
C18 columns are the most widely used reversed phase columns in the market. These are 
exceptionally well suited for the separation of lipids based on their chain lengths. However 
when used in the separation of C1P species using a methanol/water – methanol system a 
recurring problem has been carryovers between samples, sometimes in excess of 10%. This 
is especially the case for C16 C1P.  A method used by Kester et al was shown to have less 
carryover using the same solvent system with the addition of tetrahydrofuran (THF) and 
heating of the column.  Use of THF with heating causes a gummy substance to build up on 
the ESI source face plate leading to progressive deterioration of the signal when running 
multiple samples. Use of the methanol/water – methanol system by itself, together with the 
column heating and an extended run for 10 minutes was found to be sufficient to address 
the problem of carryover without the need for THF thereby avoiding the undesirable side 
effects. Using this method the column carryover after 10 injections of 10 pmols each of D-
e-C12 C1P was less than 1%. 
 
Heating of the column result in an increase of the signal strength and thereby 
the sensitivity due to increased the ionization efficiency of C1P. 
 
In order to compare any detrimental effects on signal strength due to heating of the 
column, same quantity of D-e-C12 C1P was analyzed using the published protocol and the 
131 
modified protocol. Almost a two fold increase in the signal strength for C1P was achieved 
due to heating of the column to 60 0C (Figure 4.4) 
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Figure 4.4: Heating of the C18 reverse phase column result in a two fold increase in 
signal strength. 8 pmols of D-e-C12 C1P was analyzed using a C18 reverse phase column 
as described in materials and methods with the column either heated at 60 0C or maintained 
at room temperature. The data are an average of 10 injections ± SD 
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The analytes are well separated in the modified method allowing for successful 
quantitation. 
 
The standards by themselves and a mixture of long chain naturally occurring C1P’s were 
analyzed using this modified method. The long chain bases and their phosphates elute first 
while the C1P’s did not elute until the chromatographic conditions changed to 100% 
methanol. This separation allows for separately scanning for the two analyte groups there 
by allowing for additional increase in the sensitivity (Figures 4.5 and 4.6). 
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Figure 4.5: Excited Ion Chromatogram for LC-MS/MS from the reverse phase 
separation of standards used in the quantitation of long chain bases, long chain base 1 
phosphates and C1P. Long chain bases and their phosphates elute first. 
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Figure 4.5: Excited Ion Chromatogram for LC-MS/MS from the reverse phase 
separation of selected synthetic C1P species.  Separation was carried out using the 
modified HPLC protocol. All biologically relevent C1P species are eluting at 100 % 
methanol. 
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Sample dry down without proper neutralization causes SM to breakdown to C1P. 
 
Previously C1P has been shown to be present in A549 cells in significant quantities. 
However the protocol used involved drying down the samples tested in a basic solution.  
We decided to test the possibility of lipid degradation due to drying under basic conditions. 
To our surprise the neutralized samples had three fold lower C1P than the un-neutralized. 
Examination of the SL fraction revealed SM to have decreased by a similar amount 
suggesting to us that during drying under basic conditions, SM is getting broken down to 
C1P (Figure 4.6A and 4.6B).  
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Figure 4.6A: Sample dry down following base hydrolysis without proper 
neutralization leads to increased amounts of C1P being present in the samples. A549 
cells were plated on 10 cm plates in the appropriate medium and grown at 370C under 5% 
CO2 overnight. The next day, cells were harvested and lipids were extracted as mentioned 
in materials and methods. Following base hydrolysis one group of lipid extracts were dried 
down without neutralization (■) while the other dried down following neutralization (□). 
All samples were brought up in reversed phase loading buffer and subjected to analysis by 
HPLC-ESI MS/MS as described in materials and methods.  The data are an average of 3 
samples ±SD. 
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Figure 4.6B: Sample dry down following base hydrolysis without proper 
neutralization leads to decreased amounts of SM being present in the samples. A549 
cells were plated on 10 cm plates in the appropriate medium and grown at 370C under 5% 
CO2 overnight. The next day, cells were harvested and lipids were extracted as mentioned 
in materials and methods. Following base hydrolysis one group of lipid extracts were dried 
down without neutralization (■) while the other dried down following neutralization (□). 
All samples were brought up in reversed phase loading buffer and subjected to analysis by 
HPLC-ESI MS/MS as described in materials and methods.  The data are an average of 3 
samples ±SD. 
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The modified method has a linear quantitation range from 5 fmoles to >125 pmol 
when used with 4000 QTRAP mass spectrometer. 
 
Current generation of mass spectrometers very often show sub pico molar sensitivities. 
However this sensitivity is mainly dependent on the ionization capability of the analyte 
under investigation. The fact that the naturally occurring levels of C1P is almost two orders 
of magnitude lower than previously reported brought to question the validity of using the 
previously used levels of internal standards for quantitation of C1P. Also of interest is the 
linear range of quantitation of the modified method. To investigate these questions, 
different quantities of the internal standard mix used was analyzed for LCB’s (d17:1 
sphingosine, d17:1 sphinganine, d17:1 sphingosine-1-phosphate and d17:1 sphinganine-1-
phosphate) and C1P (d18:1/12:0 C1P) using the now developed method. The amounts injected 
ranged from 5 femto moles to 125 pmols.  Within this range all analytes tested showed 
linear signal response with increasing concentrations. This confirmed that the use of the 
internal standard mix described by Merrill et al (99) can still be used to quantify naturally 
occurring low levels of C1P and also that femto molar levels of changes in the LCB’s can 
also be accurately quantified (Figure 4.7). 
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Figure 4.7: The modified method for detection of C1P shows a linear response in the 
range of 5 fmol to 125 pmols for C1P and LCB standards. 5 fmols to 125 pmols of 
standard solution in LCB buffer was analyzed using the method modified to overcome the 
carryover problem. The signal response as measured by the area under the peak vs the 
amount analyzed in pmols were plotted as a log-log plot. 
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D-e-C16 C1P is specifically decreased upon treatment of A549 cells with siRNA 
against Ceramide Kinase. 
 
Previous studies using steady state labeling of C1P has shown that treatment of cells with 
si-CERK result in a decrease in the levels of D-e-C16 C1P. To date mass spectrometric 
analyses have failed to confirm this finding.  Using the newly developed mass 
spectrometric assay for C1P, we quantified the levels of C1P in A549 cells where ceramide 
kinase has been down regulated by si-RNA. For the first time the results are in agreement 
with the steady state labeling data in that down regulation of CERK caused a 
corresponding decrease in the levels of D-e-C16:0 C1P (Figure 4.8). 
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Figure 4.8: siRNA mediated downregulation of endogenous CERK in  of A549 cells 
results in a concomitant decrease in the predominant C1P species. Sequence-specific 
silencing of CERT was performed using small interfering RNA (siRNA) as described in 
Experimental Procedures. 27 hours post treatment cells were harvested and the levels of 
C1P were measured using the newly developed HPLC ESI-MS/MS method. Results are 
the average of three experiments ± SD. 
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DISCUSSION: 
 
Several times over, C1P has been shown to be an important bioactive molecules with 
activities implicated in biological processes that range from DNA synthesis to mast cell 
degranulation to apoptosis to name a few. Our laboratory has repeatedly shown the 
importance of C1P in inflammation by acting as an activator of cPLA2α. However, studies 
into metabolism of C1P has been hampered by the lack of a reliable and preferably 
nonradioactive method for detecting and quantifying cellular levels of C1P. The data 
generated using the currently available mass spectrometric methods were inconsistent with 
the levels of C1P measured using steady state labeling studies. In fact the levels of C1P 
were almost two orders of magnitude greater than expected. Here for the first time we 
describe a method that is validated using steady state labeling studies and thus can be used 
to reliably quantify cellular C1P levels. 
 
C1P is not an easily ionizable species. Thus the signal strength is relatively low compared 
to S1P under the eluting conditions. This result in poor sensitivity and is especially a 
problem when trying to quantify low levels of C1P. As a result greater quantities of 
starting material is required. This is especially a problem when the starting material are 
from costly experiments like siRNA mediated gene knockdown. Thus any improvement is 
signal strength will help to bring down the amount of starting material needed.  As 
indicated by Figure 4.2 and additional benefit of using a heated column is the twofold 
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increase in signal strength obtained. This now allows for lower quantities of starting 
material to be successfully analyzed for C1P. 
 
A major hurdle to overcome in the development of the method was the absence of a 
commercially available panel of C1P’s of different chain lengths to be used as standards. 
This problem is compounded by the appearance of in properly neutralized samples 
multiple peaks corresponding to a particular transition. This resulted in difficulties in the 
unambiguous assignment of peaks to the corresponding C1P species. To overcome this 
technical hurdle, C1P species of different chain lengths had to be custom synthesized at 
great cost. However, the discovery that one of the main problems of the existing method, 
namely the overestimation of C1P species due to the breakdown of SM (Figure 4.7A and 
4.7B), turned out to be quite useful. This discovery was to our advantage since the same 
process allowed us to generate C1P that can be used to verify the retention times of the 
different chain lengths of C1P allowing for unambiguous peak assignment.  
 
In summary, we have developed a HPLC ESI-MS/MS method that  quantify cellular levels 
of C1P that are in agreement with the levels of C1P found to be present by steady state 
labeling studies. Using this method we have shown that, contrary to previous reports, the 
bioactive molecule C1P is present only in low abundance in cells. Ceramide Kinase, the 
only enzyme identified to date to produce C1P does not seem to be responsible for all the 
C1P species in cells. With the ever increasing use and the continuing decline in prize, mass 
spectrometers are becoming more commonplace in research institutes. The sub pico molar 
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sensitivity coupled with the availability of multiple levels molecular identification 
(molecular weight of the intact molecule, presence of signature fragments, retention time 
etc) are making mass spectrometers the most versatile bio-analytical tools available. 
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CHAPTER 5:  SEARCH FOR THE ALTERNATE SOURCE(S) OF C1P 
 
INTRODUCTION 
 
The sphingolipid metabolite ceramide 1 phosphate was described by Gomez-Munoz. Since 
then the number of biological activities attributed to C1P has been steadily increasing 
further increasing its recognition as an important lipid signaling molecule. Currently C1P  
has been demonstrated to play a role in DNA synthesis, activation of cPLA2α leading to 
the production of inflammatory mediators, degranulation of mast cells, inhibition of 
apoptosis via inhibition of aSMase. 
 
Until recently the only known source of C1P has been ceramide kinase. However, siRNA 
mediated knockdown of ceramide kinase (80% knockdown) have consistently failed to 
decrease C1P levels by an amount proportional to the knockdown. Recent publicatons by 
Boath et al (107) and Graf et al (96) with regards to ceramide kinase knockout mouse has 
confirmed these findings by our laboratory. This raise the question as to what the other 
sources of C1P are. Here, using steady state labeling and the validated  mass spectrometric 
methods  we developed, we have attempted to identify the alternate source of C1P in 
mammalian cells. 
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EXPERIMENTAL PROCEDURES 
 
Materials:  CERK knockout mice was a donation as a result of  collaboration with 
Frederick Bornancin (Novartis, Switzerland). 
 
Cell culture: Mouse embryo fibroblasts were harvested from 5 day old embryos and 
cultured sunder standard incubator conditions in DMEM (4.5 g glucose l-1) (BioWhittaker) 
supplemented with 10% fetal bovine serum (Invitrogen) and 2% penicillin/streptomycin 
(BioWhittaker). A549 cells were obtained from the American Type Culture Collection. 
A549 lung adenocarcinoma cells were grown in 50% DMEM (BioWhittaker) and 50% 
RPMI (BioWhittaker) supplemented with 10% fetal bovine serum (Invitrogen) and 2% 
penicillin/streptomycin (BioWhittaker). Cells were maintained under 5% CO2 at 370 C by 
routine passage every 3 days. For treatments, the medium was replaced 2 h before the 
addition of the agonist by DMEM containing 2% fetal bovine serum and 2% 
penicillin/streptomycin. 
 
Treatment of cells with lipids:  Ethanol and dodecane is mixed at a ratio of 98:2, followed 
by vortexing and pre-warmed at 37 °C. Meanwhile, the lipid is dissolved in 
chloroform:methanol 1:1. The required volume is then dried down under N2 gas.  The pre-
warmed alcohol:dodecane mixture is added to the dried C1P such that the final 
concentration is 2.5 mM (a stock solution up to 10 mM can be made). This mixture is 
thoroughly vortexed and incubated at 37°C for a further 20 minutes followed by further 
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vortexing. The stock solution, thus prepared, is diluted to the required concentration using 
ethanol/dodecane and used to treat the cells. This is incubated at 37 °C followed by 
vortexing. Lipid solution is diluted to the appropriate concentration in ethanol/dodecane 
solution, and added to cells at a dilution of 1:1000.  
 
Pulse labeling and thin layer chromatographic detection of C1P: Pulse labeling. A549 
cells were plated on 10 cm dishes at the concentration of 1.3 106 cells per plate. The next 
day, [32P]orthophosphate (Perkin-Elmer) was added at 30 mCi/ml for 4 h. following 
incubation the cells were treated for two hour with the relevant lipid. The plates were then 
placed on ice, and the lipids were extracted using the Bligh and Dyer method followed by a 
base hydrolysis with 0.4 M methanolic NaOH for 2 h at 37 0C. The samples were dried 
under N2 and resuspended in chloroform-methanol (75:25) and spotted onto a 10 x 10 cm 
TLC plate (silica gel) (VWR International) together with standards. The lipids were 
separated using a chloroform-acetone-methanol-acetic acid-water (10:4:3:2:1) solvent 
mixture. The 32P-labeled lipids were detected by exposing the plates to X-ray film. 
 
Mass spectrometric analysis: A549 cells were plated on 10 cm plates in the appropriate 
medium and grown at 370C under 5% CO2 overnight. The next day, cells were subjected 
to the relevant treatment. After treatment, the plates were placed on ice and the cells were 
washed once with ice cold PBS and harvested by scraping in 200 µl of PBS. An aliquot of 
cells was taken for standardization (total protein). Lipids were extracted from the 
remaining cells as described by Merrill et al with slight modifications.  In summary, to the 
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remaining cells 1 ml of methanol was added and sonicated to obtain a homogeneous mix 
followed by the addion of 500 µl of chloroform and 500 pmols of internal standards 
(Avanti). Internal standards used were d18:1/12:0 ceramide-1-phosphate sphingomyelin, 
ceramide, glucosylceramide, lactosylceramide and d17:1-sphingosine, sphinganine, 
sphingosine-1-phosphate, sphinganine-1-phosphate. The mixture was sonicated once again 
and incubated overnight at 480C. Following day the extracts was subjected to base 
hydrolysis for 2 hrs at 37 0C and neutralized. The neutralization was confirmed with pH 
paper. Half of the extract was transferred to another tube, dried down and resuspended in 
LCB running buffer C1P together with the long chain bases were quantified using the 
modified protocol from Merrill et al (99). To the remainder of the extract 1ml of 
chloroform and 2ml of water were added, and the lower phase was transferred to another 
tube, dried down and brought up in SL running buffer and used in the analysis of 
ceramides, monohexosyl ceramides and sphingomyelins and described by Merrill et al 
(99). The lipids were separated using a Discovery C18 column on a Shimadzu HPLC and 
subjected to mass spectrometric analysis using a 4000 Q-Trap (Applied Biosystems). 
Multiple reaction monitoring (MRM) transiton monitored were 562.4/264.4 (d18:1/12:0), 
590.4/264.4 (d18:1/14:0), 618.4/264.4 (d18:1/16:0), 620.4/264.4 (d18:0/16:0), 644.4/264.4 
(d18:1/18:1), 646.4/264.4 (d18:1/18:0), 674.4/264.4 (d18:1/20:0), 702.4/264.4 (d18:1/22:0), 
728.4/264.4 (d18:1/24:1), 730.4/264.4 (d18:1/24:0), 756.4/264.4 (d18:1/26:1), 758.4/264.4 (d18:1/26:0) 
were used at collision energies +41, +43.5, +43.5, +46.0, +46.0, +48.5, +51.0, +53.5, 
+56.0, +56.0, +58.5, +58.5 V respectively.  
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pairs used were was carried out using m/z 644.6 (molecular ion) and m/z 78.9 (PO3 22 
ion) for C12 C1P. The chromatography apparatus for C1P was a 5 cm3 2.1mmDiscovery 
C18 5mmHPLC column. The mobile phase solvent A for LCB and C1P was 58:41:1 
CH3OH/water/HCOOH and solvent B was 99:1 CH3OH/HCOOH. Both contained 5 mM 
ammonium formate (26). The mobile phase foe solvent A for sphingolipids are A: CH3CN: 
H2O:CH3COOH 97:2:1, and solvent B: CH3OH : H2O : CH3(CH2)2CH2OH : CH3COOH 
64:15:20:1. Both contained 5mM ammonium acetate. 
 
 
RESULTS 
 
C16 C1P is specifically decreased in the embryonic fibroblasts of ceramide kinase 
knockout mice.  
 
Currently two groups have published phenotypic data on ceramide kinase knockout mice. 
Both groups report the mice being as aphenotypical with slightly altered C1P profiles (108-
110).  A collaboration with Novartis (Switzerland) allowed us to establish a ceramide 
kinase knockout mouse breeding colony together with their wild type counterparts. This 
enabled us to harvest and use mouse embryonic fibroblasts in assaying the effects of 
ceramide kinase knockdown on cellular physiology. We first compared changes in the C1P 
profiles of MEF’s between ceramide kinase knockout mice and their wild type 
counterparts. The data revealed that the levels of C16 C1P is reduced by half in the 
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embryonic fibroblasts of the knockout mice compared to those of wild type mice. The 
other chain lengths of C1P were not affected (Figure 5.1).  
Figure 5.1: CERK -/- mice has decreased levels of C16 C1P. Mouse embryo fibroblasts 
obtained from CERK +/+ and -/- mice were cultured upto passage 3 as indicated in 
materials and methods. At passage 3 same number of cells were plated in 10 cm plates and 
allowed to adhere overnight. These cells were harvested and the lipids were extracted and 
quantified as described in materials and methods. The data show is the mean of three 
experiments ±SD. 
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Treatment of A549 cells with radiolabeled S1P results in an increase of radiolabeled 
C1P. 
 
The presence of C1P in ceramide kinase knockout model is a clear indication as to the 
presence of additional sources of C1P. One possibility is via the acylation of S1P. To 
investigate this, 32P labeled S1P was delivered to cells via ethanol/dodecane. The lipids 
were extracted from these cells and separated by TLC together with the standards as 
mentioned in materials and methods. The treatment resulted in an increase in radiolabeled 
C16 C1P.  
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Figure 5.2A: Treatment of A549 cells with 32P labeled S1P results in an increase in 32P 
labeled C1P. A549 cells rested for two hours in % FBS containing A549 medium were 
treated with a mix of radiolabeled and unlabeled S1P 500 nM for two hours in 2% medium 
Following treatment cells were harvested and lipids extracted followed by thin layer 
chromatography as described in materials and methods. The results are representative of 
three separate reactions from three separate reactions. 
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Figure 5.2B: Treatment of HBEC cells with 32P labeled S1P results in an increase in 
32P labeled C1P. HBEC cells rested for two hours in % FBS containing HBEC medium 
were treated with a mix of radiolabeled and unlabeled S1P 500 nM for two hours in 2% 
medium Following treatment cells were harvested and lipids extracted followed by thin 
layer chromatography as described in materials and methods. The results are representative 
of three separate reactions from three separate reactions. 
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Treatment of ceramide kinase knockout mouse embryo fibroblasts with d17:1 S1P 
results in an increase of d17:1 C1P 
 
Radiolabeling studies demonstrated that S1P can be acylated to produce C16 C1P.  The 
levels of this lipid in A549 cells where ceramide kinase is downregulated by siRNA is half 
that of the cells with normal levels of CERK (Chapter 4 Figure 4.8). Similar effects are 
observed in the MEF’s of CERK knockout mice. All these data indicates an alternate 
source of C1P. We hypothized that acylation of S1P is responsible at least in part for the 
CERK independent generation of C16 C1P. To investigate this possibility, we treated 
CERK knockout MEF with d17:1 S1P and looked for the occurrence of d17:1 C1P by mass 
spectrometry. The results show that the major portion of d17:1 C1P is d17:1/16:0 species 
(Figure 5.3). 
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Figure 5.3:  S1P is acylated into C16 C1P in ceramide kinase knockout MEF’s. 
Ceramide kinase knockout MEF’s were treated with d17:1 S1P (500 nM) for two hours. 
Following incubation, the lipids were extracted from the cells and subjected to analysis by 
mass spectroscopy. The data are an average of three experiments ± SD. 
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DISCUSSION: 
 
Currently C1P has been implicated in many biological processes. The only enzyme found 
to produce C1P directly is ceramide kinase. However, down regulation of CERK by 
siRNA has not resulted in proportional downregulation of C1P indicating the presence of 
alternate sources of C1P. Similar results were observed with CERK knockout mice. 
Downregulation of C1P was however found to be chain length specific in both instances 
with D-e-C16 C1P being downregulated by around 50%. This leads to the interesting 
possibility that CERK is mainly involved in the generation of the 16 C chain length of 
C1P. Since our previous published results prove that the substrate specificity of CERK 
with regards to all chain lengths longer than 14 C are more or less the same, the specific 
decrease in C16 C1P observed here would be due to an availability effect.  
 
Many possibilities exist that may account for the CERK independent C1P in cells. These 
include an as yet undiscovered enzyme with a Smase D function; an unidentified novel 
enzyme with a ceramide kinase function or an enzyme capable of acylating S1P and 
thereby producing C1P. We decided to investigate this last possibility. Currently there are 
6 identified ceramide synthases expressed in mammalian cells. The substrate specificity of 
all these are not well studied. Therefore the possibility exists that at least one may be able 
to use S1P as the substrate to produce C1P. To this extent, delivery of 32P labeled S1P to 
cells resulted in an increase of 32P labeled C1P indicating the existence of an acylation 
pathway for the synthesis of C1P from S1P (Figures 5.2A and 5.2B). This hypothesis is 
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further strengthened by the observation that treatment of cells with d17:1 S1P also resulted 
in an increase in d17:1 C1P.  Taken together these observations provide compelling 
evidence for generation of C1P via a pathway that involve a direct conversion of S1P. 
 
The fact that the major form of C1P through the acylation pathway investigated above was 
C16 C1P raises the interesting possibility that the remaining C16 C1P in cells that do not 
contain CERK is via an acylation pathway. C16 C1P is the major form of C1P in cells. The 
availability of multiple pathways to produce the lipid indicate that it is an important lipid in 
the function of the cell. Also of importance is the fact that the acylation of S1P did not 
result in a significant increase in the other forms of C1P. This would indicate the presence 
of additional pathways for the synthesis of those different chain lengths of C1P. 
 
In summary the study confirms previous studies that CERK is responsible for only a subset 
of C1P found in cells (namely C16 C1P). The data provides compelling evidence for the 
existence of an acylation pathway for production of C1P from S1P. The main form of C1P 
produced via this pathway appears to be C16 C1P. This seems to indicate the existence of 
other pathways that are responsible for other chain lengths of C1P. Taken together the data 
indicate that C1P is an important lipid in cells with multiple pathways responsible for its 
production. Further studies are needed to identify the particular acylase responsible for 
production of C1P from S1P 
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APPENDIX A.1 
Table A.1. AB 4000 Mass Spectrometer settings and retention times for reverse 
chromatographic separation under the described conditions for long chain bases, long chain 
base phosphates and C1P. 
 Precursor 
ion m/z 
Product 
ion m/z 
DP CE CXP Retention 
time 
d17:1 So 286.40 268.30 135.00 15.00 15.00 0.569 
d17:1 Sa 288.40 260.20 50.00 21.00 15.00 0.688 
d18:1 So 300.50 282.30 50.00 21.00 16.00 0.587 
d18:1 So 302.50 284.30 50.00 23.00 16.00 0.725 
d17:1 So1P 366.40 250.40 50.00 23.00 16.00 0.706 
d17:1 Sa1P 368.40 252.40 50.00 25.00 16.00 0.844 
d18:1 So1P 380.40 264.40 81.00 25.00 16.00 0.954 
d18:1 Sa1P 382.40 266.40 81.00 25.00 16.00 0.697 
d18:1/2:0 C1P 422.30 264.40 81.00 27.50 16.00 1.21 
d18:1/12:0 C1P 562.40 264.40 81.00 41.00 16.00 3.24 
d18:1/14:0 C1P 590.40 264.40 81.00 43.50 16.00 3.44 
d18:1/16:0 C1P 618.50 264.40 81.00 46.00 16.00 3.82 
d18:0/16:0 C1P 620.50 266.40 81.00 46.00 16.00 3.95 
168 
d18:1/18:1 C1P 644.50 264.40 81.00 48.50 16.00 3.85 
d18:1/18:0 C1P 646.50 264.40 81.00 48.50 16.00 4.05 
d18:1/20:0 C1P 674.60 264.40 81.00 51.00 16.00 4.15 
d18:1/22:0 C1P 702.70 264.40 81.00 53.50 16.00 4.38 
d18:1/24:1 C1P 728.60 264.40 81.00 56.00 16.00 4.58 
d18:1/24:0 C1P 730.60 264.40 81.00 56.00 16.00 4.66 
d18:1/26:1 C1P 756.70 264.40 81.00 58.50 16.00 4.68 
d18:1/26:0 C1P 758.70 264.40 81.00 58.50 16.00 4.71 
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